benzoyl peroxide profile

Benzoyl peroxide is a synthetic organic compound with the formula (C6H5CO)2O2. It is a white, crystalline solid that is insoluble in water but soluble in most organic solvents. It is primarily used as an acne treatment, as it is an effective antibacterial and anti-inflammatory agent. Benzoyl peroxide works by killing the bacteria that cause acne and reducing inflammation. It also helps to prevent the formation of new acne lesions. Benzoyl peroxide is typically applied to the skin as a cream, lotion, or gel. It is available over-the-counter and by prescription. Side effects of benzoyl peroxide include dryness, redness, peeling, and irritation. It is important to use benzoyl peroxide as directed and to avoid contact with the eyes and mouth. Benzoyl peroxide is a powerful oxidizing agent and should be handled with care. It is also sensitive to light and should be stored in a cool, dry place.'

Benzoyl Peroxide: A peroxide derivative that has been used topically for BURNS and as a dermatologic agent in the treatment of ACNE and POISON IVY DERMATITIS. It is used also as a bleach in the food industry. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Products

ID Source	ID
PubMed CID	7187
CHEMBL ID	1200370
CHEBI ID	82405
SCHEMBL ID	63
MeSH ID	M0002375

Synonym
BIDD:GT0840
smr000058568
MLS000028899
benzoyl peroxide (jan/usp)
D03093
bepio (tn)
clearasil bp acne treatment cream
debroxide
benzac w
clearasil antibacterial acne lotion
dibenzoylperoxyde [dutch]
lucidol-70
akneroxide l
desquam-x
lucidol (peroxide)
acnegel
incidol
b 75w
desquam x
stri-dex b.p
cadox b 50p
benzoyl peroxide [usan]
garox
benzashave
cadox b 70w
dibenzoylperoxid [german]
nsc 671
cadox b
phisoac bp
clear by design
novadelox
oxy-5
desquam e
quinolor compound
benoxyl (5&10) lotion
topex
nayper b and bo
acne-aid cream
benbel c
vanoxide
xerac
benzaknen
luperox fl
cadox b-ch 50
bzf-60
brevoxyl
loroxide
ccris 630
aksil 5
benzoylperoxyde [dutch]
benzagel 10
hsdb 372
novadelox (18% benzoyl peroxide, 78% calcium sulphate, 4% magnesium carbonate)
epi clear antiseptic lotion
oxy-10
norox bzp-c-35
cadox 40e
desanden
cadox b 40e
cadat bpo
xerac bp
oxy-10 cover
luperco aa
perossido di benzoile [italian]
cadox bs
peroxyde de benzoyle [french]
norox bzp-250
benzagel
aztec bpo
lucidol 50p
superox 744
benox 50
lucidol kl 50
chaloxyd bp 50ft
abcat 40
einecs 202-327-6
fostex bpo
benzoylperoxid [german]
g 20
benzoyl
diphenylperoxyanhydride
benzoyl benzenecarboperoxoate
bpo ,
inchi=1/c14h10o4/c15-13(11-7-3-1-4-8-11)17-18-14(16)12-9-5-2-6-10-12/h1-10
benzoylperoxyde
component of oxy-5
nsc-671
lucidol g 20
panoxyl
persa-gel
mytolac
benzoic acid, peroxide
wln: rvoovr
benzoylperoxid
94-36-0
acetoxyl
asidopan
theraderm
oxy 5
peroxyde de benzoyle
nsc-675
eloxyl
benoxyl
dry and clear
persadox
benzac
dibenzoylperoxyde
diphenylglyoxal peroxide
dibenzoyl peroxide
akneroxid 5
oxylite
benzoyl peroxide
nsc671
nsc675
benzoperoxide
epi-clear
luperco ast
benzoyl superoxide
peroxide, dibenzoyl
dibenzoylperoxid
component of vanoxide
duresthin 5
lucidol b 50
resdan akne
perossido di benzoile
nayper bo
benzol peroxide
lucidol
luperox(r) atc50, benzoyl peroxide, ~50 wt. % in tricresyl phosphate
luperox(r) a75fp, benzoyl peroxide, 75% remainder water, contains 25 wt. % water as stabilizer, 75%
luperox(r) a75, benzoyl peroxide, 75%, remainder water
luperox(r) a70s, benzoyl peroxide, 70%, remainder water
NCGC00159380-04
NCGC00159380-02
NCGC00159380-03
peroxide, benzoyl
diphenylglyoxal superoxide
superoxide, benzoyl
superoxide, diphenylglyoxal
luperox(r) a98, benzoyl peroxide, reagent grade, >=98%
HMS2092F22
B3152
e928
anhydrous benzoyl peroxide
benzoylis peroxidum cum aqua
benzoyl peroxide anhydrous
chebi:82405 ,
CHEMBL1200370
epsolay
hydrous benzoyl peroxide
ins-928
ins no.928
e-928
AKOS000120600
A844933
benzenecarboperoxoic acid benzoyl ester
phenylcarbonyl benzenecarboperoxoate
NCGC00159380-05
C19346
cas-94-36-0
dtxcid001072
dtxsid6024591 ,
tox21_111619
nsc758205
nsc-758205
pharmakon1600-01503004
stri-dex b.p.
w9wzn9a0gm ,
benprox
benzoyl peroxide gel
neobenz micro
unii-w9wzn9a0gm
pacnex
fostex bpo bar, gel, and wash
benzoyl peroxide [usan:usp]
benzefoam
ec 202-327-6
lavoclen
SC10147
benzoyl peroxide component of benzamycin
duac component benzoyl peroxide
benzoyl peroxide [iarc]
hydrous benzoyl peroxide [usp monograph]
benzaclin component benzoyl peroxide
hydrous benzoyl peroxide [who-ip]
benzoyl peroxide component of epiduo
benzoyl peroxide component of acanya
benzoyl peroxide [who-dd]
idp-126 component benzoyl peroxide
benzoyl peroxide [inci]
benzoyl peroxide component of benzaclin
acanya component benzoyl peroxide
epiduo component benzoyl peroxide
benzoyl peroxide [hsdb]
benzoyl peroxide component of duac
benzoyl peroxide component of twyneo
benzamycin component benzoyl peroxide
benzoyl peroxide [jan]
benzoyl peroxide [mi]
twyneo component benzoyl peroxide
benzoyl peroxide [mart.]
benzoyl peroxide [usp impurity]
benzoylperoxide
benzoylis peroxidum cum aqua [who-ip latin]
benzoyl peroxide [fcc]
benzoyl peroxide [vandf]
benzoyl peroxide [orange book]
BP-21236
CCG-213090
SCHEMBL63
tox21_111619_1
dibenzoylperoxide
bezoyl peroxide
benzoyl peroxyde
benzoyl-peroxide
bisbenzoyl peroxide
dibenzoy lperoxide
bis benzoylperoxide
di-benzoylperoxide
benzoic peroxyanhydride
dibenzoyl-peroxide
bbpo
bzoobz
di-benzoyl peroxide
lucidol 70
dibenzoyl peroxyde
triaz
lucidol 78
sulfoxyl (salt/mix)
diphenylperoxyanhydride #
w 75
peroxyderm
clearasil bp acne treatment
nsc 675
un 2088
cadet bpo 78w
xerac bp (salt/mix)
lucidol 75fp
oxy wash
akneroxid l
xerac bp 5
na 2085 (dot)
nyper b
un 2085 (dot)
oxy-l
superox
luzidol
xerac bp 10
abcure s-40-25
preoxydex
un 2086
nyper bmt
benzagel (salt/mix)
component of vanoxide (salt/mix)
perkadox 20s
peroxydex
benzaknew
dermoxyl
cadet
clearasil benzoyl peroxide lotion
cuticura acne cream
sanoxit
nericur
fostex bpo (salt/mix)
2685-64-5
AB01562988_01
bepio
DB09096
mfcd00003071
benzoyl peroxide, 97% (dry wt.), wet with 25% water
F0001-2260
benzoyl peroxide, remainder water
sr-05000001817
SR-05000001817-1
benzoyl peroxide, saj first grade, >=98.0% dry basis
benzoyl peroxide blend with dicyclohexyl phthalate, technical, ~50% (t)
benzoyl peroxide, for synthesis, 72.0-80.0%
dibenzoylperoxid (german)
benzoyl peroxide (luperox(r) a75fp)
acetoxyl 2.5 and 5
periygel
lucidol-78
presadox
luperox a98
lucilite
luperco afr-250
luperco afr
luperco ac
aztec benzoyl peroxide-70-77
benzoyl peroxide (luperox(r) a98)
benzoyl peroxide (usp)
luperco a
benzoyl peroxide, blend in dibutyl phthalate
benzoyl peroxide (luperox(r) a70s)
benzoylperoxid (german)
benzoyl peroxide, blend in tricresyl phosphate
cadet bpo-70w
benzoyl peroxide, usan
benzoyl peroxide (usan)
lucidol gs
thermaderm
cadox btw-50
benzoyl peroxide (luperox(r) a75)
aztec benzoyl peroxide-dry
lucidol rm
cadox bta
novadeiox
lucipal
benzoyl peroxide(usan)
florox
benzoyl peroide
cadox bpo-w40
SBI-0206719.P001
triaz;dibenzoyl peroxide
Q411424
Z104489074
BRD-K59986511-001-02-3
peroxyl
BR1012
luperox(r) a75, benzoyl peroxide 75%, remainder water
androstan-17-one, 3-(acetyloxy)-5-bromo-6,19-epoxy-, (3b,5a,6b)-
breakout clearing emergency spot fix
relovox
meijer acne treatmentacne medication
spotless regimen for acne, blemishes and breakouts
benzoil 12hr acne treatment
skinpharmacy advanced acne therapy active clearing
dermaharmony 10% benzoyl peroxide
benzepro
replenix acne solution benzoyl peroxide wash
oil-free acne cleanser
walgreens acne control cleanser
breakout clearing daytime treatment
controlling cream
zapzyt acne
neutrogena acne control
medpura benzoyl peroxideaqueous base, acne treatment gel
o skin acne
lintera wash
oxy 10 acne cleanser
neutrogena clear pore cleanser mask
rugby benzoyl peroxideacne medication
oil free deep cleansing duo cleansing brush oil free acne cleanser
benzoyl perozide
md-acne body acne treatment
skinpharmacy advanced acne therapytargeted treatment wipes
rugby benzoyl peroxide
cetaphil gentle clear bpo acne cleanser
face values acne medication
terminator 10
benzoyl peroxide 2.50%
targeted acne spot treatmentcvs
ocean seas dermatology acne treatment cleanser
replenix acne
pca skin bpo cleanser
meijer maximum strength foaming acne face wash
acne vanishing gel-10%
acne face and body wash
dermisaclear skin
oxyadvanced care rapid spot treatment
benzoyl peroxide wash
o skin acne benzoyl wash
meijer acne foaming cleanser
acne spot repair
walgreens acne foaming washacne medication
lucidol 98
benzoyl peroxideacne medication
clear med10%
oxy 5tinted
oxy face washmaximum aciton
acne spot corrector
daily acne control cleanser
reform
cleanseracne clearing treatment
touch acne treatment
acne control serum
safewayacne treatment
vanishing acne treatment creamcvs health
oxy 10vanishing
acne free oil free acne cleanser 2.5 benzoyl peroxide
rodan and fieldsunblemish-acne medicated
family care acne treatment
benzoyl peroxide 5% gel
proactivextra strength formula treatment
slmd am benzoyl peroxide acne treatment
oxy face wash
skinpharmacy advanced acne therapy
bpo-3
meijer acne foaming cleanseracne treatment
bpt10.1 acne treatment
ca22 benzoyl peroxide cleansing
target up and up acne medication
slmd bp body wash
anti bac acne clearing
hydrous benzoyl peroxide (usp monograph)
skinpharmacy advanced acne therapy spot treatment
breakout controlbioelements
walgreens acne foaming cleanser
slmd spot treatment
24 hour acne serum
5 percent benzoyl peroxide cleanser
cvs health maximum strength acne treatment
solimo repairing treatment for acne prone skin
proactiv renewing cleanser
triderma acne spot treatment
sanperox bpo
acne10%
bp wash
benzoyl peroxide 4%
vanishing acne treatmentdaylogic
glossier zit stick breakout eraser
neutracure restore
acne therapy
acne forte acne treatment cream
neutrogena rapid clear stubborn acne cleanser
acne tx mask
3 step acne systemwell at walgreens
cleargenix advanced acne treatment
111 medco benzoyl peroxide
clear med
sacheu spot eraser
neutrogena stubborn acne am treatment
acne foaming washdaylodic
meijer maximum strength foaming acne face washacne medication
equate purifying cleanser
benzoazeline forte
equate acne washacne medication
oxy sensitive face washmaximum soothing
bevoline
rugby benzoyl peroxide wash
glytone acne bpo treatment gel
revitolacne treatment
breakout control
rugby acne medication benzoyl peroxide
blemish
af foam clear skin acne pore cleanser
lucidol bt 50
solimo renewing cleanser for acne prone skin
acne wipeout all day breakout control
avene cleanance acne medicated clearing treatment
creamy acne face wash
crmy acne washcvs
bp acne spot treatment
advanced acne wash
10% benzoyl peroxide acne medication
pr benzoyl peroxide wash
cvs health quick action spot treatment
superox 46-750
humane acne spot treatment
dermaharmony 5% benzoyl peroxide
advanced 3 in 1 exfoliating cleanser
acne free free 24 hr acne clearing system
all-in-one
rugby benzoyl peroxide washacne medication
bpt3.1 acne treatment
clear proof acne treatmentacne medication
dual-shave 2 in 1for her
acne solutionsclearing moisturizer acne medication
benzoyl peroxide 5%
vie naturelle acne body
tc 1 (peroxide)
cvs health concealing acne treatment maximum strength adult acne treatment
let me be perfectly clear
oxy rapid spot treatmentmaximum action
neutrogena on-the-spot acne treatmentvanishing formula
oxytotal care clarifying moisturizer
targeted acne spot treatment
clean and clear persa-gel 10
serious skincare continuously clear clearz it
spotless daily acne wash
daily leave on acne treatment mask
modesaacne treatment
dermaharmony 5% benzoyl peroxidecleansing bar
good neighbor pharmacy acne treatment
acne med 2.5%
oxy 10
naturium benzoyl peroxide cream cleanser 5%
proactiv plus pore targeting treatment
o skin acnemoderate
dr song acne
acne defense daily treatment serummerle norman
cvs health maximum strength acne treatmentacne medication
benzoyl peroxide (iarc)
equate clear complexion facial cleanser
lucidol bw 50t
spotless acne clearing treatment
pumice cleansing scrub-2.5% benzoyl peroxide
oxyadvanced care soothing cream acne cleanser
unblem est
obliterate
iblanc restora-brightacne healing
nyper bs
proactiv emergency blemish relief
benzoyl peroxide 4.00%
zapzyt acne treatment gel
amazon basics acne foaming cleanser
nyper ff-k
meijer invisible acne
perrigo benzoyl peroxidehydroalcoholic base
ab skincare acne spot treatment

Excerpt	Reference	Relevance
"Benzoyl peroxide (BPO) is a commonly used flour whitener, but its excessive usage can have adverse effects on human health, such as nutrient loss, vitamin deficiencies and certain diseases. "	( An intelligent smartphone-test strip detection platform for rapid and on-site sensing of benzoyl peroxide in flour samples. Fan, J; Feng, X; Li, R; Liu, X; Luo, L; Zhang, X; Zhao, B, 2023)	2.57
"Benzoyl peroxide soap is a treatment for acne, but evidence regarding its effectiveness as prophylaxis in shoulder surgery is lacking."	( Randomized controlled trial of chlorhexidine wash versus benzoyl peroxide soap for home surgical preparation: neither is effective in removing Cutibacterium from the skin of shoulder arthroplasty patients. Gong, D; Hsu, JE; Matsen, FA; Napierala, MA; Whitson, AJ; Woodhead, BM, 2020)	1.52
"Benzoyl peroxide (BPO) is a widely used over-the-counter (OTC) topical acne treatment often used in combination with salicylic acid (SA) to achieve better comedone control than that achieved with BPO alone. "	( Evaluation of the efficacy, tolerability, and safety of an over-the-counter acne regimen containing benzoyl peroxide and salicylic acid in subjects with acne. Butners, V; Eastern, J; Green, LJ; Gwazdauskas, J; Kircik, LH, 2013)	2.05
"Benzoyl peroxide (BPO) is a cornerstone of acne therapy, often used in combination with a topical antibiotic and/or a retinoid. "	( Tolerability and irritation potential of four topical acne regimens in healthy subjects. Grove, G; Gwazdauskas, J; Zerweck, C, 2013)	1.83
"Benzoyl peroxide (BPO) is a commonly used and highly effective topical treatment for acne that is available in concentrations from 2.5-10%. "	( Benzoyl peroxide development, pharmacology, formulation and clinical uses in topical fixed-combinations. Harper, JC, 2010)	3.25
"Benzoyl peroxide (BPO) is a strong oxidizing agent and widely used as flour bleaching agent. "	( Effects of flour bleaching agent on mice liver antioxidant status and ATPases. Jia, X; Liu, P; Wu, Y, 2011)	1.81
"Benzoyl peroxide (BPO) is a commonly used drug in the treatment of acne vulgaris, but it induces unwanted side effects related to stratum corneum (SC) function. "	( Topical alpha-tocotrienol supplementation inhibits lipid peroxidation but fails to mitigate increased transepidermal water loss after benzoyl peroxide treatment of human skin. Han, N; Luu, C; Packer, L; Thiele, JJ; Valacchi, G; Weber, S; Weber, SU, 2003)	1.97
"Benzoyl peroxide (BP) is a first-line topical treatment in acne vulgaris (AV). "	( Efficacy and safety of stabilised hydrogen peroxide cream (Crystacide) in mild-to-moderate acne vulgaris: a randomised, controlled trial versus benzoyl peroxide gel. Bigardi, A; Milani, M; Zavattarelli, M, 2003)	1.96
"Benzoyl peroxide (BP) is an initiator of polymerisation used in the synthesis of methyl methacrylate dental materials, and is a known allergen that causes allergic contact dermatitis during occupational exposure, especially in dentists and dental personnel. "	( Presenting an in vitro cell culture model to determine the cytotoxic effect of benzoyl peroxide vapours. Bester, MJ; Erasmus, F; Pretorius, E, 2003)	1.99
"Benzoyl peroxide is a non-antibiotic antibacterial agent that is bactericidal against P."	( Topical antibacterial treatments for acne vulgaris : comparative review and guide to selection. Tan, HH, 2004)	1.04
"Benzoyl peroxide is a free-radical generating compound widely used in the polymer industry and also in pharmaceuticals as antimicrobial agent to treat acne. "	( Effect of alpha-tocopherol and N-acetylcysteine on benzoyl peroxide toxicity in human keratinocytes. Albertazzi, A; Bellei, E; Bergamini, S; Iannone, A; Manfredini, P; Rota, C; Tomasi, A, 2004)	2.02
"Benzoyl peroxide is a powerful antimicrobial agent that rapidly destroys both bacterial organisms and yeasts."	( Topical antibacterial therapy for acne vulgaris. Dreno, B, 2004)	1.04
"Benzoyl peroxide was found to be a potent promoter as reported previously."	( Studies on the promoting and complete carcinogenic activities of some oxidizing chemicals in skin carcinogenesis. Hayashi, Y; Imazawa, T; Kurokawa, Y; Matsushima, Y; Takamura, N, 1984)	0.99
"Benzoyl peroxide is a powerful oxiding agent with broad spectrum germicidal activity and good liposolubility. "	( Utility of topical benzoyl peroxide for prevention of surgical skin wound infection. Bencini, PL; Galimberti, M; Signorini, M, 1994)	2.06
"Benzoyl peroxide (BzPO) is a free radical generating compound that acts as a tumor promoter and progressor in mouse skin. "	( Generation of DNA base modification following treatment of cultured murine keratinocytes with benzoyl peroxide. Egner, PA; Kensler, TW; King, JK, 1996)	1.96
"Benzoyl peroxide is a known tumor promoter and progression agent in mouse skin, though it is not an initiator or complete carcinogen. "	( Benzoyl peroxide-induced damage to DNA and its components: direct evidence for the generation of base adducts, sugar radicals, and strand breaks. Davies, MJ; Hazlewood, C, 1996)	3.18
"Benzoyl peroxide (BPO) is an effective cutaneous tumor promoter acting through the generation of oxidative stress, induction of ornithine decarboxylase activity and by enhancing DNA synthesis."	( Attenuation of benzoyl peroxide-mediated cutaneous oxidative stress and hyperproliferative response by the prophylactic treatment of mice with spearmint (Mentha spicata). Alam, A; Saleem, M; Sultana, S, 2000)	1.38
"Benzoyl peroxide is an effective cutaneous tumor promoter acting through the generation of oxidative stress, the induction of ornithine decarboxylase activity and the enhancement of DNA synthesis."	( Lupeol, a triterpene, inhibits early responses of tumor promotion induced by benzoyl peroxide in murine skin. Ahmed, B; Alam, A; Arifin, S; Saleem, M; Shah, MS; Sultana, S, 2001)	1.26
"Benzoyl peroxide is a bleaching agent typically used to give such flour a better appearance."	( Determination of benzoyl peroxide and benzoic acid levels by HPLC during wheat flour bleaching process. Fritz, R; Manrique, GD; Saiz, AI, 2001)	1.37
"Benzoyl peroxide is a useful agent in the treatment of acne, chronic ulcers, tinea pedis, and tinea versicolor, probably because of its antimicrobial power. "	( New uses for benzoyl peroxide: a broad-spectrum antimicrobial agent. Kligman, AM; Leyden, JJ; Stewart, R, 1977)	2.07
"Benzoyl peroxide is a powerful antibacterial agent."	( [Acne and its drug treatment]. Büchner, SA, 1990)	1
"Benzoyl peroxide (BP) is shown to be a weak allergen. "	( Allergic and irritant potential of benzoyl peroxide. Haustein, UF; Tegetmeyer, L; Ziegler, V, 1985)	1.99

Excerpt	Reference	Relevance
"Benzoyl peroxide has a proven track record of safety and efficacy, and can decrease reliance on antibiotics in the treatment of acne."	( Advancement in benzoyl peroxide-based acne treatment: methods to increase both efficacy and tolerability. Fakhouri, T; Feldman, SR; Yentzer, BA, 2009)	1.43
"Benzoyl peroxide has a proven track record of safety and efficacy for the treatment of acne. "	( Advancement in benzoyl peroxide-based acne treatment: methods to increase both efficacy and tolerability. Fakhouri, T; Feldman, SR; Yentzer, BA, 2009)	2.15
"Benzoyl peroxide (BPO) has been used extensively in industry and health care for more than a century and has been approved for the treatment of acne for over 60 years. "	( Sixty Years of Benzoyl Peroxide Use in Dermatology. Baldwin, H; Elewski, B; Hamil, K; Harper, J; Hougeir, F; Levy-Hacham, O; Yamauchi, P, 2023)	2.71
"Benzoyl peroxide (BPO) has been widely used to treat acne vulgaris. "	( [Mechanism of Inhibitory Effects of Cherry Bark-containing Jumihaidokuto on Benzoyl Peroxide Induced Erythema in Hairless Mice]. Han, LK; Michihara, S; Sejima, T; Takahashi, R; Zhang, Q, 2020)	2.23
"Benzoyl peroxide (BPO) has been well established as a common medication for acne vulgaris in many countries (e.g. "	( Clinical efficacy and safety of benzoyl peroxide for acne vulgaris: Comparison between Japanese and Western patients. Doi, M; Kawashima, M; Nagare, T, 2017)	2.18
"Benzoyl peroxide (BPO) has been a mainstay of topical acne treatment for years. "	( Skin delivery aspects of benzoyl peroxide-loaded solid lipid nanoparticles for acne treatment. Barhate, GA; Bhosale, SH; Kyadarkunte, AY; Mendiratta, C; Pokharkar, VB, 2014)	2.15
"Benzoyl peroxide has a proven track record of safety and efficacy, and can decrease reliance on antibiotics in the treatment of acne."	( Advancement in benzoyl peroxide-based acne treatment: methods to increase both efficacy and tolerability. Fakhouri, T; Feldman, SR; Yentzer, BA, 2009)	1.43
"Benzoyl peroxide has a proven track record of safety and efficacy for the treatment of acne. "	( Advancement in benzoyl peroxide-based acne treatment: methods to increase both efficacy and tolerability. Fakhouri, T; Feldman, SR; Yentzer, BA, 2009)	2.15
"Benzoyl peroxide has antibiotic activity as well as anticomedogenic properties."	( A randomized, double-blind, multicenter, parallel group study to compare relative efficacies of the topical gels 3% erythromycin/5% benzoyl peroxide and 0.025% tretinoin/erythromycin 4% in the treatment of moderate acne vulgaris of the face. Amin, S; Choi, K; Goldstein, E; Gupta, AK; Kunynetz, RA; Lynde, CW, )	1.06
"Benzoyl peroxide (BP) has been a standard and effective topical treatment for acne vulgaris for the past 35 years. "	( Delayed type hypersensitivity to benzoyl peroxide. Lowenstein, EJ; Shwereb, C, )	1.86
"Benzoyl peroxide (BPO) has been an important component of the acne treatment armamentarium for decades. "	( New developments in topical antimicrobial therapy for acne. Leyden, J, 2008)	1.79
"Benzoyl peroxide (BzPO) has been the most widely used topical agent for acne since the 1960s. "	( Effect of benzoyl peroxide on protein kinase C in cultured human epidermal keratinocytes. DeLeo, VA; Matsui, MS; Mintz, E, 1995)	2.14
"Benzoyl peroxide also has antimicrobial, antipruriginous and antifungal properties all of them contributing to shorten the evolution of the lesions."	( [Benzoyl peroxide in the treatment of decubitus ulcers]. Almenara Barrios, J; Alonso Blasi, N; Alonso Trujillo, F; Fernández Vozmediano, JM; Lafuente, L, 1988)	1.91

Excerpt	Reference	Relevance
"Benzoyl peroxide formulations suppress the follicular population of P. "	( Comparative efficacy of clindamycin and benzoyl peroxide for in vivo suppression of Propionibacterium acnes. Gans, EH; Kligman, AM, 2002)	2.02
"Benzoyl peroxide caused an increase of 10.5% in sebum production on the forehead, 10.3% on the chin and 25.4% on the cheek."	( Relationship between sebostatic activity, tolerability and efficacy of three topical drugs to treat mild to moderate acne. Bragadin, G; Patrone, P; Pillon, B; Stinco, G; Trotter, D, 2007)	1.06

Excerpt	Reference	Relevance
"Benzoyl peroxide soap is a treatment for acne, but evidence regarding its effectiveness as prophylaxis in shoulder surgery is lacking."	( Randomized controlled trial of chlorhexidine wash versus benzoyl peroxide soap for home surgical preparation: neither is effective in removing Cutibacterium from the skin of shoulder arthroplasty patients. Gong, D; Hsu, JE; Matsen, FA; Napierala, MA; Whitson, AJ; Woodhead, BM, 2020)	1.52
"Benzoyl peroxide treatment (20 mg/animal/0.2 ml acetone) and UVB radiation (0.420 J/m(2)/s) caused a decrease in the activities of cutaneous antioxidant enzymes namely, catalase, glutathione peroxidase, glutathione reductase, glucose-6-phosphate dehydrogenase, phase II metabolizing enzyme such as glutathione-S-transferase and quinone reductase and depletion in the level of cutaneous glutathione."	( Inhibition of benzoyl peroxide and ultraviolet-B radiation induced oxidative stress and tumor promotion markers by cycloartenol in murine skin. Alam, A; Khan, N; Sharma, S; Sultana, S, 2003)	1.4
"Benzoyl peroxide treatment alone caused less marked increases in epidermal and dermal measures compared with ultraviolet B under the conditions used."	( The effects of radicals compared with UVB as initiating species for the induction of chronic cutaneous photodamage. Ibbotson, SH; Kochevar, IE; Moran, MN; Nash, JF, 1999)	1.02
"Benzoyl peroxide treatment increases cutaneous microsomal lipid peroxidation and hydrogen peroxide generation."	( Lupeol, a triterpene, inhibits early responses of tumor promotion induced by benzoyl peroxide in murine skin. Ahmed, B; Alam, A; Arifin, S; Saleem, M; Shah, MS; Sultana, S, 2001)	1.26
"Treatment with benzoyl peroxide 5%/clindamycin phosphate 1% gel significantly (P<.001) reduced P acnes levels by >1 log10/cm2 from baseline (91% inhibition) 24 hours after application."	( Effect of topical benzoyl peroxide/clindamycin versus topical clindamycin and vehicle in the reduction of Propionibacterium acnes. Leyden, JJ, 2002)	0.99
"Treatment with benzoyl peroxide and the combination of erythromycin and benzoyl peroxide resulted in a significant reduction in the number of aerobic bacteria without any change in the resistance pattern to erythromycin or other antibiotics."	( Antibiotic resistance patterns in coagulase-negative staphylococci after treatment with topical erythromycin, benzoyl peroxide, and combination therapy. Foglia, AN; Fried, F; Harkaway, KS; Lee, WL; Leyden, JJ; McGinley, KJ; Shalita, AR, 1992)	0.84
"The treatment with benzoyl peroxide alone leads to both a generalized hyperpigmentation and skin scaling without formation of any tumors."	( Benzoyl peroxide promotes the formation of melanotic tumors in the skin of 7,12-dimethylbenz[a]anthracene-initiated Syrian golden hamsters. Edler, L; Goerttler, K; Loehrke, H; Schweizer, J, 1987)	2.03

Excerpt	Reference	Relevance
" A broad spectrum of model toxic compounds was evaluated for toxicity on mouse skin JB6 cells in culture."	( Studies of skin toxicity in vitro: dose-response studies on JB6 cells. Berezesky, IK; Fitzpatrick, MJ; Jain, PT; Phelps, PC; Trump, BF, 1992)	0.28
"Topical benzoyl peroxide has been used in the treatment of acne for over 30 years, with no reports of adverse effects that could be related to skin carcinogenesis."	( Benzoyl peroxide: an integrated human safety assessment for carcinogenicity. Binder, RL; Kraus, AL; LeBoeuf, RA; Munro, IC; Orr, JC; Williams, GM, 1995)	2.17
"3%) adverse event with all three therapies."	( The efficacy and safety of a combination benzoyl peroxide/clindamycin topical gel compared with benzoyl peroxide alone and a benzoyl peroxide/erythromycin combination product. Hickman, JG; Jarratt, MT; Levy, SF; Leyden, JJ; Stewart, DM, )	0.4
" The most frequent adverse effect, dry skin, occurred to a similar extent in the combination and benzoyl peroxide treatment groups."	( Comparison of the efficacy and safety of a combination topical gel formulation of benzoyl peroxide and clindamycin with benzoyl peroxide, clindamycin and vehicle gel in the treatments of acne vulgaris. Berger, RS; Connolly, MA; Dunlap, FE; Ellis, CN; Levy, SF; Leyden, JJ, 2001)	0.75
" Reported and theoretical adverse effects from systemic exposure are detailed."	( Topical acne drugs: review of clinical properties, systemic exposure, and safety. Akhavan, A; Bershad, S, 2003)	0.32
" Adverse events were rare in all subjects."	( Compared efficacy and safety of tretinoin 0.1% microsphere gel alone and in combination with benzoyl peroxide 6% cleanser for the treatment of acne vulgaris. Anderson, DN; Landow, S; Lee, WL; Rafal, ES; Shalita, AR; Yavel, R, 2003)	0.54
" Furthermore, the authors concluded that the permanent L929 mouse fibroblast cell line can provide valuable information regarding the cytotoxic effects of dental products and associated compounds that form toxic vapours."	( Presenting an in vitro cell culture model to determine the cytotoxic effect of benzoyl peroxide vapours. Bester, MJ; Erasmus, F; Pretorius, E, 2003)	0.55
" The safety assessment was conducted through reports regarding adverse reactions and local tolerance in all visits and an overall tolerance at the end of the study."	( Single-blind and comparative clinical study of the efficacy and safety of benzoyl peroxide 4% gel (BID) and adapalene 0.1% Gel (QD) in the treatment of acne vulgaris for 11 weeks. de C Almeida, F; de Faria, FA; do Nascimento, LV; Guedes, AC; Guerra, RM; Magalhães, GM, 2003)	0.55
" Evaluations included lesion count reduction, subject's assessment of acne, adverse events, and cutaneous tolerability."	( Long-term safety and efficacy of a unique fixed-dose combination gel of adapalene 0.1% and benzoyl peroxide 2.5% for the treatment of acne vulgaris. Gold, MH; Graeber, M; Liu, Y; Morris, A; Pariser, DM; Westmoreland, P, 2007)	0.56
" Discontinuations due to adverse events were low (2."	( Long-term safety and efficacy of a unique fixed-dose combination gel of adapalene 0.1% and benzoyl peroxide 2.5% for the treatment of acne vulgaris. Gold, MH; Graeber, M; Liu, Y; Morris, A; Pariser, DM; Westmoreland, P, 2007)	0.56
"These findings are consistent with previous clinical findings and support the use of a once-daily adapalene/BP fixed-dose combination as a safe and effective treatment in the long-term management of acne."	( Long-term safety and efficacy of a unique fixed-dose combination gel of adapalene 0.1% and benzoyl peroxide 2.5% for the treatment of acne vulgaris. Gold, MH; Graeber, M; Liu, Y; Morris, A; Pariser, DM; Westmoreland, P, 2007)	0.56
" No substantive differences were seen in cutaneous tolerability among treatment groups and less than 1% of patients discontinued treatment because of adverse events."	( An aqueous gel fixed combination of clindamycin phosphate 1.2% and benzoyl peroxide 2.5% for the once-daily treatment of moderate to severe acne vulgaris: assessment of efficacy and safety in 2813 patients. Calvarese, B; Chen, D; Thiboutot, D; Webster, G; Weiss, J; Zaenglein, A, 2008)	0.58
" While both regimens were safe and effective, regimen BPO/C+RAM yielded a more rapid onset of effect versus regimen CPT+BPO against both non-inflammatory and inflammatory lesions."	( Comparative efficacy and safety results of two topical combination acne regimens. Kircik, LH, 2009)	0.35
" Our results show that BPO and the combination of BPO and clindamycin do not accelerate photocarcinogenesis, but are toxic in hairless mice."	( Photocarcinogenesis and toxicity of benzoyl peroxide in hairless mice after simulated solar radiation. Lerche, CM; Philipsen, PA; Poulsen, T; Wulf, HC, 2010)	0.64
" Treatment-related adverse events (AEs) occurred in 48."	( Study of the efficacy, tolerability, and safety of 2 fixed-dose combination gels in the management of acne vulgaris. Alió, AB; Barnard, J; Fischer, TC; Wohlrab, J; Zouboulis, CC, 2009)	0.35
"We, the Food and Drug Administration (FDA), are issuing this final rule to include benzoyl peroxide as a generally recognized as safe and effective (GRASE) active ingredient in over-the-counter (OTC) topical acne drug products."	( Classification of benzoyl peroxide as safe and effective and revision of labeling to drug facts format; topical acne drug products for over-the-counter human use; final rule. , 2010)	0.92
" The morning/morning regimen is a safe and effective treatment option for patients with moderate acne vulgaris."	( Tretinoin gel microsphere pump 0.04% plus 5% benzoyl peroxide wash for treatment of acne vulgaris: morning/morning regimen is as effective and safe as morning/evening regimen. Bucko, A; Fried, R; Jarratt, MT; Kempers, S; Kircik, L; Lucky, AW; Nighland, M; Pariser, D; Rafal, E; Ramaswamy, R; Rendon, M; Rossi, AB; Weiss, J; Wilson, DC, 2010)	0.62
"5% (adapalene-BPO) is efficacious and safe in the treatment of acne patients aged 12 years or older, as demonstrated in three randomized and controlled studies."	( Treatment of 2,453 acne vulgaris patients aged 12-17 years with the fixed-dose adapalene-benzoyl peroxide combination topical gel: efficacy and safety. Dirschka, T; Eichenfield, LE; Graeber, M; Jorizzo, JL; Kerrouche, N; Lynde, C; Taub, AF, 2010)	0.58
" We report the fourth published case of acne vulgaris treated with isotretinoin in an individual with CGD, with a safe and successful outcome."	( Safe and successful treatment of acne vulgaris with isotretinoin in a patient with chronic granulomatous disease. Alonso-de-Celada, RM; de-Lucas Laguna, R, )	0.13
" Safety assessments included skin tolerability and adverse events (AEs)."	( Safety and efficacy of clindamycin phosphate 1.2%-benzoyl peroxide 3% fixed-dose combination gel for the treatment of acne vulgaris: a phase 3, multicenter, randomized, double-blind, active- and vehicle-controlled study. Alió Sáenz, AB; Eichenfield, LF, 2011)	0.62
" Cutaneous adverse events were not statistically different in using combination therapy compared with T/CP alone."	( Efficacy and safety of tretinoin 0.025%/clindamycin phosphate 1.2% gel in combination with benzoyl peroxide 6% cleansing cloths for the treatment of facial acne vulgaris. Haddican, M; Linkner, RV; Wong, V; Zeichner, JA, 2013)	0.61
" Safety was assessed through evaluations of adverse events (AEs) and local tolerability [erythema, scaling, dryness, and stinging/burning on scales ranging from 0 (none) to 3 (severe)]."	( Preadolescent moderate acne vulgaris: a randomized trial of the efficacy and safety of topical adapalene-benzoyl peroxides. Draelos, Z; Eichenfield, LF; Hebert, AA; Liu, H; Lucky, AW; Manna, V; Rudisill, D; Stein Gold, L; Sugarman, J, 2013)	0.6
" The changes of acne lesion count (efficacy), any adverse effect (safety), and the patients' overall satisfaction (tolerability) were compared after 3 months of follow-up."	( The efficacy, safety, and tolerability of adapalene versus benzoyl peroxide in the treatment of mild acne vulgaris: a randomized trial. Babaeinejad, SH; Fouladi, RF, 2013)	0.63
" The changes of acne lesion count (efficacy), any adverse effect (safety), and the patients' overall satisfaction (tolerability) were compared after 3 months of follow-up."	( The efficacy, safety and tolerability of adapalene versus benzoyl peroxide in the treatment of mild acne vulgaris; a randomized trial. Babaeinejad, SH; Fouladi, RF, 2013)	0.63
" Based on the results from this analysis, adapalene-BPO is a safe and effective treatment for acne in black skin."	( A subgroup analysis to evaluate the efficacy and safety of adapalene-benzoyl peroxide topical gel in black subjects with moderate acne. Alexis, AF; Callender, VD; Johnson, LA; Kerrouche, N, 2014)	0.64
"A topical fixed-dose clindamycin phosphate 1·2% and benzoyl peroxide 3·0% combination gel (CLNP/BPO 3%) is known to be effective and safe in white people with acne."	( Clindamycin phosphate 1·2%-benzoyl peroxide 3·0% fixed-dose combination gel has an effective and acceptable safety and tolerability profile for the treatment of acne vulgaris in Japanese patients: a phase III, multicentre, randomised, single-blinded, acti Alió Sáenz, AB; Hashimoto, H; Kawashima, M; Ono, M; Yamada, M, 2015)	0.96
" Safety assessments included adverse events (AEs), laboratory tests, vital signs and local skin tolerability."	( Clindamycin phosphate 1·2%-benzoyl peroxide 3·0% fixed-dose combination gel has an effective and acceptable safety and tolerability profile for the treatment of acne vulgaris in Japanese patients: a phase III, multicentre, randomised, single-blinded, acti Alió Sáenz, AB; Hashimoto, H; Kawashima, M; Ono, M; Yamada, M, 2015)	0.71
" The incidence of adverse drug reactions was higher for CLNP/BPO 3·0% once (24·0%) or twice (35·1%) daily than for CLNP twice daily (9·0%)."	( Clindamycin phosphate 1·2%-benzoyl peroxide 3·0% fixed-dose combination gel has an effective and acceptable safety and tolerability profile for the treatment of acne vulgaris in Japanese patients: a phase III, multicentre, randomised, single-blinded, acti Alió Sáenz, AB; Hashimoto, H; Kawashima, M; Ono, M; Yamada, M, 2015)	0.71
" All adverse events were mild or moderate."	( Is benzoyl peroxide 3% topical gel effective and safe in the treatment of acne vulgaris in Japanese patients? A multicenter, randomized, double-blind, vehicle-controlled, parallel-group study. Alio Sáenz, AB; Hashimoto, H; Kawashima, M; Ono, M; Yamada, M, 2014)	1.02
" No serious adverse events were reported."	( Safety and efficacy of adapalene 0.1% / benzoyl peroxide 2.5% in the long-term treatment of predominantly moderate acne with or without concomitant medication - results from the non-interventional cohort study ELANG. Friedrich, M; Gollnick, HP; Jäckel, A; Jöstingmeyer, P; Peschen, M; Pettker, R; Pier, A; Porombka, D; Rojo Pulido, I; Streit, V, 2015)	0.68
"In consistence with previous clinical findings, the use of adapalene-BPO in daily practice routine is safe and effective in the long-term management of patients with moderate to severe acne."	( Safety and efficacy of adapalene 0.1% / benzoyl peroxide 2.5% in the long-term treatment of predominantly moderate acne with or without concomitant medication - results from the non-interventional cohort study ELANG. Friedrich, M; Gollnick, HP; Jäckel, A; Jöstingmeyer, P; Peschen, M; Pettker, R; Pier, A; Porombka, D; Rojo Pulido, I; Streit, V, 2015)	0.68
" Safety was evaluated based on adverse events, local skin tolerability scores and laboratory test values."	( Open-label, randomized, multicenter, phase III study to evaluate the safety and efficacy of benzoyl peroxide gel in long-term use in patients with acne vulgaris: A secondary publication. Katsuramaki, T; Kawashima, M; Nagare, T, 2017)	0.68
" Safety assessment also showed that the incidence of adverse events was higher in Japanese patients than in Western patients, but the characteristics of the adverse events were not different."	( Clinical efficacy and safety of benzoyl peroxide for acne vulgaris: Comparison between Japanese and Western patients. Doi, M; Kawashima, M; Nagare, T, 2017)	0.74
" Safety assessments included adverse events (AEs) and tolerability."	( Efficacy and Safety of Adapalene 0.3%/Benzoyl Peroxide 2.5% Gel Plus Oral Doxycycline in Subjects With Severe Inflammatory Acne Who Are Candidates for Oral Isotretinoin. Baldwin, H; Del Rosso, JQ; Johnson, SM; Lain, EL; Landis, M; Rendon, M; Rueda, MJ; Stein Gold, L; Tanghetti, E; Weiss, J, 2018)	0.75
"3% A/BPO + DOX is an effective and safe treatment option for severe inflammatory AV, before starting OI treatment, or as an alternative when OI cannot be used."	( Efficacy and Safety of Adapalene 0.3%/Benzoyl Peroxide 2.5% Gel Plus Oral Doxycycline in Subjects With Severe Inflammatory Acne Who Are Candidates for Oral Isotretinoin. Baldwin, H; Del Rosso, JQ; Johnson, SM; Lain, EL; Landis, M; Rendon, M; Rueda, MJ; Stein Gold, L; Tanghetti, E; Weiss, J, 2018)	0.75
" No untoward adverse events, visible irritation, or significant flare-up were observed."	( Safety and Efficacy of Topically Applied Selected Cutibacterium acnes Strains over Five Weeks in Patients with Acne Vulgaris: An Open-label, Pilot Study. Brüggemann, H; Gollnick, H; Güell, M; Karoglan, A; Paetzold, B; Pereira de Lima, J; Schanze, D; Tüting, T, 2019)	0.51
"The most common adverse event of epidermal growth factor receptor inhibitors, used to treat colorectal, non-small cell lung, and head and neck cancers, is acneiform eruption, with a profound effect on treatment continuation."	( Efficacy and safety of topical benzoyl peroxide for prolonged acneiform eruptions induced by cetuximab and panitumumab: A multicenter, phase II trial. Aiba, S; Kikuchi, K; Namikawa, K; Nozawa, K; Takashima, A; Tsuchiyama, K; Tsutsui, K; Yamazaki, N, 2021)	0.91
" The standard treatment involves topical and oral antibiotics, retinoids, benzoyl peroxide, and other synthetic compounds, mostly associated with adverse effects."	( Clinical study to assess efficacy and safety of Purifying Neem Face Wash in prevention and reduction of acne in healthy adults. Gajjar, T; Kumawat, R; Patel, N; Rajaiah Yogesh, H, 2022)	0.95
" Treatment-emergent adverse events and cutaneous safety/tolerability were also assessed."	( Efficacy and Safety of a Fixed-Dose Clindamycin Phosphate 1.2%, Benzoyl Peroxide 3.1%, and Adapalene 0.15% Gel for Moderate-to-Severe Acne: A Randomized Phase II Study of the First Triple-Combination Drug. Baldwin, H; Beer, K; Bhatt, V; Callender, V; Draelos, Z; Gold, M; Kircik, LH; Lain, E; Pariser, DM; Pillai, R; Sadick, N; Stein Gold, L; Tanghetti, EA; Weiss, JS, 2022)	0.96
" IDP-126 was well tolerated, with most treatment-emergent adverse events of mild-to-moderate severity."	( Efficacy and Safety of a Fixed-Dose Clindamycin Phosphate 1.2%, Benzoyl Peroxide 3.1%, and Adapalene 0.15% Gel for Moderate-to-Severe Acne: A Randomized Phase II Study of the First Triple-Combination Drug. Baldwin, H; Beer, K; Bhatt, V; Callender, V; Draelos, Z; Gold, M; Kircik, LH; Lain, E; Pariser, DM; Pillai, R; Sadick, N; Stein Gold, L; Tanghetti, EA; Weiss, JS, 2022)	0.96

Excerpt	Reference	Relevance
" Five days a week, the three materials (benzoyl peroxide, clindamycin phosphate, and erythromycin) were applied in a nonocclusive manner either alone or in combination with adapalene gel on seven cutaneous sites on the upper back."	( Skin tolerance of adapalene 0.1% gel in combination with other topical antiacne treatments. Caron, D; Clucas, A; Sorba, V; Verschoore, M, 1997)	0.56
"By week 12, dapsone gel combined with any of the three additional treatments reduced the mean number of inflammatory lesions."	( Dapsone gel 5% in combination with adapalene gel 0.1%, benzoyl peroxide gel 4% or moisturizer for the treatment of acne vulgaris: a 12-week, randomized, double-blind study. Abramovits, W; Eichenfield, LF; Fleischer, AB; Garrett, S; Lucky, A; Shalita, A, 2010)	0.61
"Dapsone gel in combination with adapalene gel or benzoyl peroxide gel is safe and well tolerated for the treatment of acne vulgaris."	( Dapsone gel 5% in combination with adapalene gel 0.1%, benzoyl peroxide gel 4% or moisturizer for the treatment of acne vulgaris: a 12-week, randomized, double-blind study. Abramovits, W; Eichenfield, LF; Fleischer, AB; Garrett, S; Lucky, A; Shalita, A, 2010)	0.86
" The objective of this experimental study was to determine the wear of tibial polyethylene inserts combined with metallic and ceramic femoral components under third-body wear conditions initiated by bone cement particles."	( Third-body abrasive wear of tibial polyethylene inserts combined with metallic and ceramic femoral components in a knee simulator study. Bader, R; Bergschmidt, P; Lange, R; Mittelmeier, W; Zietz, C, 2013)	0.39
" Tibial polyethylene inserts were combined with the identical femoral component design, but made of two different materials (cobalt-chromium and ceramic)."	( Third-body abrasive wear of tibial polyethylene inserts combined with metallic and ceramic femoral components in a knee simulator study. Bader, R; Bergschmidt, P; Lange, R; Mittelmeier, W; Zietz, C, 2013)	0.39
"The average gravimetrical wear of the tibial polyethylene inserts in combination with  cobalt-chromium and ceramic femoral components under third-body wear conditions amounted to 31."	( Third-body abrasive wear of tibial polyethylene inserts combined with metallic and ceramic femoral components in a knee simulator study. Bader, R; Bergschmidt, P; Lange, R; Mittelmeier, W; Zietz, C, 2013)	0.39
"The wear simulator test demonstrates that wear of polyethylene inserts under third-body wear conditions, in combination with ceramic femoral components, was significantly lower than with metallic femoral components."	( Third-body abrasive wear of tibial polyethylene inserts combined with metallic and ceramic femoral components in a knee simulator study. Bader, R; Bergschmidt, P; Lange, R; Mittelmeier, W; Zietz, C, 2013)	0.39
"2% (T/CP) gel in combination with a benzoyl peroxide 6% foaming cloth compared with T/CP alone for facial acne."	( Efficacy and safety of tretinoin 0.025%/clindamycin phosphate 1.2% gel in combination with benzoyl peroxide 6% cleansing cloths for the treatment of facial acne vulgaris. Haddican, M; Linkner, RV; Wong, V; Zeichner, JA, 2013)	0.89
"In conclusion, the tested skincare combined with a fixed adapalene and benzoyl peroxide combination provides a significant adjunctive efficacy and local tolerance benefit in adult women with mild acne."	( A skincare combined with combination of adapalene and benzoyl peroxide provides a significant adjunctive efficacy and local tolerance benefit in adult women with mild acne. Bouloc, A; Chadoutaud, B; Dréno, B; Imko-Walczuk, B; Moga, A; Roo, E, 2017)	0.94

Excerpt	Reference	Relevance
" These results are interpreted in terms of bioavailability of the active substances."	( Imidazoles and benzoyl peroxide: a comparative trial of two treatment schedules. Decroix, J; Tennstedt, D; Van Neste, D, 1986)	0.62
" A solubilized formulation of BPO has been developed to maximize its bioavailability and enhance follicular penetration."	( Solubilized benzoyl peroxide versus benzoyl peroxide/clindamycin in the treatment of moderate acne. Dhawan, S; Kircik, L; Tanghetti, E; Wilson, D, 2008)	0.72
"A 3-step acne system has been developed to enhance the bioavailability and follicular penetration of benzoyl peroxide (BPO)."	( A 3-step acne system containing solubilized benzoyl peroxide versus clindamycin-benzoyl peroxide. Del Rosso, JQ; Eichenfield, L; Parr, L; Shalita, A; Swinyer, L; Tanghetti, E; Thiboutot, D; Tschen, E, 2009)	0.83
" Significantly enhanced dermal bioavailability (AD-2."	( Codelivery of benzoyl peroxide & adapalene using modified liposomal gel for improved acne therapy. Jain, S; Kale, DP; Katiyar, SS; Swami, R, 2018)	0.84
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."	( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019)	0.51
" Those drug-delivery forms offer convenient self-administration; obviate gastrointestinal-tract absorption and hepatic-first-pass metabolism, thereby improving bioavailability and maintaining sufficient drug concentration within the therapeutic window; and facilitate the transmission of the largest fraction of drug molecules to the target area, thus maximizing therapeutic potential and reducing systemic drug toxicity."	( A Compendium of Compounding Agents and Formulations, Part 3: Gentamicin Sulfate and Benzoyl Peroxide. Riepl, M, )	0.36

Excerpt	Relevance	Reference
" The number of colonies which developed during promoter exposure in cocultures showed a dose-response curve which differed from the dose-response curve for stimulation of growth of 308 colonies in the absence of normal keratinocytes."	( Development of an in vitro analogue of initiated mouse epidermis to study tumor promoters and antipromoters. Hennings, H; Jung, R; Michael, DM; Pettit, GR; Robinson, VA; Yuspa, SH, 1990)	0.28
" Additionally, on this dosing regimen, the peak of ODC activity shifted to approximately 4 h after the last treatment, so that the time-course of ODC induction resembled that after multiple applications of TPA."	( Characterization of the induction of ornithine decarboxylase activity by benzoyl peroxide in SENCAR mouse epidermis. Binder, RL; Motz, AA; Volpenhein, ME, 1989)	0.51
" The relapse rate on stopping antibiotics is also significantly less in patients given I g daily and this dosage did not produce any increase in side effects."	( Evaluation of a therapeutic strategy for the treatment of acne vulgaris with conventional therapy. Burke, B; Cunliffe, WJ; Greenwood, R, 1986)	0.27
" Doubling of erythromycine dosage could not prevent premenstrual exacerbation of acne."	( On therapeutic approaches to some special types of acne. Rajka, G, 1985)	0.27
" Significantly, studies in this laboratory indicated that B6C3F1 mice dosed with BZP demonstrated increased NK activity in the spleen as was observed after dosing with TPA."	( Modulation of natural killer activity by 12-O-tetradecanoylphorbol-13-acetate and benzoyl peroxide in phorbol ester-sensitive (SENCAR) and resistant (B6C3F1) mice. Chuthaputti, A; Pfeifer, RW; Updyke, LW; Yim, GK, 1988)	0.5
"A selective high-performance liquid chromatographic (HPLC) procedure for the quantitative determination of benzoyl peroxide in pharmaceutical dosage forms is described."	( Quantitative determination of benzoyl peroxide by high-performance liquid chromatography and comparison to the iodometric method. Anthony, G; Gaddipati, N; Volpe, F, 1983)	0.77
" In addition, their in vitro profiles suggest the potential for combination use, affording greater dosing flexibility."	( Optimizing topical combination therapy for the treatment of acne vulgaris. Zeichner, JA, 2012)	0.38
"Encapsulation of more than one active pharmaceutical ingredient into nanocarriers such as liposomes is an attractive approach to achieve a synergic drug effect and less complicated dosing schedules in multi-drug treatment regimes."	( Successful co-encapsulation of benzoyl peroxide and chloramphenicol in liposomes by a novel manufacturing method - dual asymmetric centrifugation. de Albuquerque Cavalcanti Jacobsen, C; Holsæter, AM; Ingebrigtsen, SG; Škalko-Basnet, N, 2017)	0.74
"The appropriate dosage and duration of topical benzoyl peroxide gel (BP) treatment of pitted keratolysis (PK) is controversial."	( Randomized, controlled trial testing the effectiveness and safety of 2.5% and 5% benzoyl peroxide for the treatment of pitted keratolysis. Bunyaratavej, S; Kiratiwongwan, R; Leeyaphan, C; Limphoka, P; Ongsri, P, 2021)	1.1

Product Category	Products
Other	40
Produits de la mer, Poissons et dérivés, Poissons, Poissons maigres, Filets de poissons, Morues, Filets de cabillaud	1
Aliments et boissons à base de végétaux, Aliments d'origine végétale, Matières grasses, Matières grasses végétales, Produits de l'olivier, Huiles, Huiles d'olive, Huiles d'olive vierges extra, Huiles d'olive vierges	1
Meats and their products, Meats, Pork and its products, Pork, Bacon, Sliced bacon	1
Seafood,Mollusc,Oysters,fr:Huîtres fines	1
Snacks, Snacks sucrés, Barres, Barres de céréales, Barres de céréales au chocolat	1
Aliments et boissons à base de végétaux, Aliments d'origine végétale, Fruits à coques et dérivés, Fruits à coques, Fruits à coques décortiqués, Noix, Cerneaux de noix	1
Viandes et dérivés, Viande de bœuf et dérivés, Viandes, Bœuf, Préparations de viande	1
Aliments et boissons à base de végétaux, Aliments d'origine végétale, Céréales et pommes de terre, Céréales et dérivés, Produits déshydratés, Pâtes alimentaires, Produits lyophilisés à reconstituer, Nouilles, Nouilles instantanées	1
Aliments et boissons à base de végétaux, Boissons, Boissons chaudes, Boissons à base de végétaux, Thés	1
Produits d'élevages, Œufs, Œufs frais	1
Snacks, Snacks sucrés, Cacao et dérivés, Chocolats	1
Aliments et boissons à base de végétaux,Aliments d'origine végétale,Aliments à base de fruits et de légumes,Surgelés,Fruits et produits dérivés,Aliments à base de plantes surgelés,Fruits,Fruits surgelés,Cerises,Griottes,Cerises surgelées	1
Produits de la mer, Poissons et dérivés, Poissons, Poissons gras, Sardines	1
Snacks, Snacks sucrés, Cacao et dérivés, Confiseries, Confiseries chocolatées	1
Plant-based foods and beverages, Plant-based foods, Fruits and vegetables based foods, Meals, Soups, Cream soups, Vegetable soups, Cream of vegetable soups, Cream of asparagus soups	1
Seafood, Canned foods, Fishes, Fatty fishes, Canned fishes, Tunas, Canned tunas	1

Product	Brand	Category	Compounds Matched from Ingredients	Date Retrieved
Solid white albacore tuna in water	Starkist	Seafood, Canned foods, Fishes, Fatty fishes, Canned fishes, Tunas, Canned tunas	pyrophosphate	2024-02-09

Class	Description
carbonyl compound	Any compound containing the carbonyl group, C=O. The term is commonly used in the restricted sense of aldehydes and ketones, although it actually includes carboxylic acids and derivatives.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein	Taxonomy	Measurement	Average (µ)	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
acetylcholinesterase	Homo sapiens (human)	Potency	3.8902	0.0025	41.7960	15,848.9004	AID1347395
thyroid hormone receptor beta isoform a	Homo sapiens (human)	Potency	0.1585	0.0100	39.5371	1,122.0200	AID588547
lamin isoform A-delta10	Homo sapiens (human)	Potency	0.0063	0.8913	12.0676	28.1838	AID1487
Spike glycoprotein	Severe acute respiratory syndrome-related coronavirus	Potency	25.1189	0.0096	10.5250	35.4813	AID1479145
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Process	via Protein(s)	Taxonomy
virion membrane	Spike glycoprotein	Severe acute respiratory syndrome-related coronavirus
[Information is prepared from geneontology information from the June-17-2024 release]

Assay ID	Title	Year	Journal	Article
AID504749	qHTS profiling for inhibitors of Plasmodium falciparum proliferation	2011	Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043	Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID1296008	Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening	2020	SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1	Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID651635	Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1347101	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630	Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay	2021	Cell reports, 04-27, Volume: 35, Issue:4	A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347108	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347092	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347099	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347407	qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection	2020	ACS chemical biology, 07-17, Volume: 15, Issue:7	High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347104	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154	Primary screen GU AMC qHTS for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347095	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347425	Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)	2019	The Journal of biological chemistry, 11-15, Volume: 294, Issue:46	Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347090	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845	Primary qHTS for Inhibitors of ATXN expression
AID1347082	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347096	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347424	RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)	2019	The Journal of biological chemistry, 11-15, Volume: 294, Issue:46	Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1346987	P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346986	P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID625279	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625283	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625290	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID588211	Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans	2010	Chemical research in toxicology, Jan, Volume: 23, Issue:1	Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID625292	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625288	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID588212	Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents	2010	Chemical research in toxicology, Jan, Volume: 23, Issue:1	Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID625291	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625286	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625280	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625285	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625281	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID588213	Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents	2010	Chemical research in toxicology, Jan, Volume: 23, Issue:1	Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID625289	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625284	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625287	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625282	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	292 (26.57)	18.7374
1990's	151 (13.74)	18.2507
2000's	290 (26.39)	29.6817
2010's	283 (25.75)	24.3611
2020's	83 (7.55)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	255 (21.45%)	5.53%
Reviews	186 (15.64%)	6.00%
Case Studies	77 (6.48%)	4.05%
Observational	4 (0.34%)	0.25%
Other	667 (56.10%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (113)

Trial Overview

Trial	Phase	Enrollment	Study Type	Start Date	Status
Efficacy of Epiduo and Adherence of Patients Between 12 to 20 Years Using This Drug First Time in the Monotherapy of Moderate Inflammatory Acne [NCT01220102]		3,113 participants (Actual)	Observational	2010-05-31	Completed
A Randomized, Double Blind, Placebo-Controlled Clinical Trial of the Effects of Oral Zinc Gluconate Among Diagnosed Acne Vulgaris Patients [NCT05096312]	Phase 4	23 participants (Actual)	Interventional	2018-12-21	Completed
Evaluation of Ankle Propriocement and Stability in Patients Affected by Traumatic Lateral Ankle Instability Before and After External Ankle Ligament Recontruction [NCT04362488]		23 participants (Actual)	Interventional	2019-02-04	Completed
A Randomized, Double-Blind, Multiple-Site, Placebo-Controlled Study Comparing Two 1% Clindamycin/5% Benzoyl Peroxide Topical Gel Formulations in the Treatment of Moderate to Severe Acne Vulgaris [NCT01044264]		602 participants (Actual)	Interventional	2007-12-31	Completed
A Phase IV, Open-Label Study Evaluating the Use of Solodyn (Minocycline HCL Extended-Release Tablets), Ziana, and Triaz Foaming Cloths as Combination Acne Therapy Prior to Treatment With Isotretinoin [NCT01206348]	Phase 4	97 participants (Actual)	Interventional	2010-09-30	Completed
Randomized Trial of Hibiclens vs Benzoyl Peroxide Soap for Surgical Preparation [NCT04021524]	Phase 4	50 participants (Actual)	Interventional	2018-09-10	Completed
A Phase 1, Single Center, Randomized, Open-Label Study to Evaluate the Bioavailability of Clindamycin From Clindamycin 1%-Benzoyl Peroxide 3% Gel, Topical Gel (Clindamycin 1%- Benzoyl Peroxide 5%), and Once Daily Gel (Clindamycin 1%-Benzoyl Peroxide 5%) i [NCT01132443]	Phase 1	72 participants (Actual)	Interventional	2010-05-06	Completed
Improvement of Perimenstrual Acne With Clindamycin Phosphate and Benzoyl Peroxide 1.2%/3.75% Combination Gel [NCT03122457]	Phase 2	22 participants (Actual)	Interventional	2017-01-01	Completed
Prospective Randomized Study to Compare Clinical Outcomes in Patients With Osteomyelitis Treated With Intravenous Antibiotics Versus Intravenous Antibiotics With an Early Switch to Oral Antibiotics [NCT02099240]	Early Phase 1	11 participants (Actual)	Interventional	2014-03-06	Terminated(stopped due to Not enough patient enrollment and lack of staffing)
Molecular and Clinical Study of the Effect of Zaxcell Versus Effezel in the Inflammatory and Scarring Process of Moderate and Severe Acne [NCT03076320]	Phase 1/Phase 2	82 participants (Actual)	Interventional	2017-03-27	Completed
The Use of Oracea and Epiduo Forte in Severe Acne Patients [NCT03457636]	Phase 4	22 participants (Actual)	Interventional	2018-03-19	Completed
A Phase 3 Multi-Center, Double-Blind, Randomized, Vehicle-Controlled Study of S6G5T-3 in the Treatment of Acne Vulgaris [NCT03761784]	Phase 3	424 participants (Actual)	Interventional	2018-12-21	Completed
A Multi-Center, Evaluator Blinded, Randomized Clinical Study to Evaluate the Efficacy and Tolerance of Two Acne Treatments on Subjects With Mild to Moderate Acne Vulgaris [NCT02698436]		103 participants (Actual)	Interventional	2016-03-31	Completed
The Comparative Efficacy of an Over the Counter Light Therapy Mask vs Over the Counter Topical Benzoyl Peroxide 2.5% and Used in Combination With Over the Counter Adapalene Gel 0.1% for Mild to Moderate Acne [NCT03650881]		0 participants (Actual)	Interventional	2018-08-07	Withdrawn(stopped due to no eligible subjects were enrolled)
Application of Epiduo(R) PUMP in Daily Practice in Patients With Inflammatory Acne [NCT02338544]		1,388 participants (Actual)	Observational	2015-01-31	Completed
Efficacy of Combination of Topical Benzoyl Peroxide and Electrocautery Skin Incision in Eradicating Cutibacterium Acnes From Surgical Wounds During Shoulder Arthroplasty [NCT05676411]	Phase 4	70 participants (Anticipated)	Interventional	2024-06-01	Not yet recruiting
A Phase 3 Multi-Center, Double-Blind, Randomized, Vehicle-Controlled Study of S6G5T-3 in the Treatment of Acne Vulgaris [NCT03761810]	Phase 3	434 participants (Actual)	Interventional	2018-12-14	Completed
Randomized, Double-Blind, Cross-Over, Vehicle Controlled Evaluation of Topical Encapsulated Benzoyl Peroxide on the Skin Microbiome and Skin Biophysical Properties [NCT05675501]	Phase 1	31 participants (Actual)	Interventional	2020-06-10	Completed
Randomized Controlled Trial Comparing the Efficacy of Adapalene 0.1% Gel to 10% Benzoyl Peroxide in Treating Molluscum Contagiosum. [NCT05536882]	Phase 3	150 participants (Anticipated)	Interventional	2023-02-28	Not yet recruiting
Clinical Study to Evaluate the Efficacy of Topical Medications Containing Benzoyl Peroxide and Sulfur in the Regression in the Short Time (24 Hours) of Moderate Acne Vulgaris Grade II (Pimples) [NCT01260571]	Phase 4	62 participants (Anticipated)	Interventional	2011-01-31	Not yet recruiting
A Multi-Center, Double Blind, Vehicle Controlled, Study of Retin-A Micro 0.04% in the Treatment of Pediatric Acne Vulgaris in Children, Ages 9 to 11 Years of Age [NCT00907335]	Phase 2	110 participants (Actual)	Interventional	2009-02-28	Completed
A Phase 4, Single-Blind, Randomized, Study to Compare the Tolerability and Efficacy of Tazorac Cream When Used in Combination With Either Duac Gel or Acanya Gel for the Treatment of Facial Acne Vulgaris [NCT01016977]	Phase 4	40 participants (Actual)	Interventional	2009-10-31	Completed
A Randomized Double Blind Multiple Center Placebo Controlled Study Comparing CLBG and Benzoyl Peroxide Gel 1%/5% to BenzaClin® (Clindamycin 1%/Benzoyl Peroxide 5%) Topical Gel in the Treatment of Acne Vulgaris [NCT02595034]	Phase 1	1,000 participants (Actual)	Interventional	2015-01-31	Completed
A Clinical Assessment of Combination Therapy With Differin® Gel, 0.3% With Duac® (Clindamycin/Benzoyl Peroxide Gel) in Subjects With Acne Vulgaris [NCT00671749]	Phase 4	100 participants (Actual)	Interventional	2007-12-31	Completed
Comparative Efficacy and Safety of Benzoyl Peroxide Used in Combination With Clindamycin vs. Benzoyl Peroxide Used in Combination With Clindamycin and Doxycycline in the Treatment of Moderate Acne [NCT00837213]	Phase 4	33 participants (Actual)	Interventional	2007-08-31	Completed
A Single-blind, Randomized, Comparative Pilot Study Evaluating the Tolerability of Two Topical Combination Therapies in the Treatment of Acne Vulgaris [NCT00887484]	Phase 4	50 participants (Actual)	Interventional	2009-02-28	Completed
A Single-blind, Randomized, Comparative Split-face Study Evaluating the Tolerability of Clindamycin and Benzoyl Peroxide Gel to Benzoyl Peroxide/Adapalene Gel in the Treatment of Acne Vulgaris. [NCT00964223]	Phase 4	28 participants (Actual)	Interventional	2009-07-31	Completed
A Randomized, Investigator Blinded, Single Site, Three Arm Clinical Study to Assess the Functional and Emotional Benefits of Replenix Power of Three Cream With Resveratrol , Replenix Power of Three Cream With Resveratrol With Adapalene and Benzoyl Peroxid [NCT03563365]	Phase 4	43 participants (Actual)	Interventional	2018-06-04	Terminated(stopped due to Lack of Funding)
Optimization of Skin Preparation to Reduce Cutibacterium Acnes Colonization in Superficial and Deep Samples During Prosthetic Shoulder Surgery in Male Patients [NCT04028401]	Phase 3	110 participants (Anticipated)	Interventional	2020-06-19	Recruiting
Multicenter, Double-blind, Randomized, Parallel-group, Placebo-controlled Study to Evaluate the Bioequivalence of a Generic Clindamycin 1.2% and Benzoyl Peroxide 3.75% Gel to Onexton® Gel in Subjects With Acne Vulgaris [NCT02616614]	Phase 3	862 participants (Actual)	Interventional	2015-05-31	Completed
An Investigator-Blind, Phase 4 Study Assessing the Facial Irritation Potential of Two Acne Treatment Products (Retin-A Micro Gel, 0.04% Pump and Epiduo Gel) Using a Split-Face Model [NCT00952523]	Phase 4	162 participants (Actual)	Interventional	2009-07-31	Completed
Efficacy of Blue Light Therapy in Reducing Cutibacterium Acnes Bioburden at the Deltopectoral Interval [NCT04300010]	Phase 4	60 participants (Actual)	Interventional	2020-10-05	Completed
A Phase 3 Multicenter, Randomized, Double-Blind, Active And Vehicle-Controlled Study Of The Safety And Efficacy Of A Clindamycin / Benzoyl Peroxide Gel Versus Clindamycin Gel Versus Benzoyl Peroxide Gel Versus Vehicle Gel In Subjects With Acne Vulgaris [NCT00776919]	Phase 3	1,315 participants (Actual)	Interventional	2008-10-31	Completed
A Multi-center, Double-blind, Randomized, Placebo, Controlled, Parallel-group Study, Comparing Adapalene/BP Gel, 0.3%/2.5% to EPIDUO® FORTE GEL and Both Active Treatments to a Placebo Control in the Treatment of Acne Vulgaris [NCT02709902]	Phase 1	460 participants (Actual)	Interventional	2015-09-30	Completed
A Prospective Multi-Center Blinded, Randomized, Controlled Clinical Trial Comparing the Efficacy of Provodine Topical Body Wash Versus 10% Benzoyl Peroxide Topical Body Wash for the Treatment of Hidradenitis Suppurativa [NCT01818167]		25 participants (Actual)	Interventional	2013-01-05	Completed
[NCT00664248]	Phase 3	1,414 participants (Actual)	Interventional	2006-10-31	Completed
A Monocentric, Single-Blind, Randomized, Placebo-Controlled Study of the Safety and Efficacy of the Topical Drug Acnase Creme in the Treatment of Acne Vulgaris I and II [NCT00877409]	Phase 3	80 participants (Anticipated)	Interventional	2009-04-30	Not yet recruiting
A Multi-Center, Randomized, Double-Blind, Parallel-Group Study to Demonstrate the Efficacy and Safety of Adapalene/Benzoyl Peroxide Topical Gel Compared With Adapalene Topical Gel, 0.1%; Benzoyl Peroxide Topical Gel, 2.5% and Topical Gel Vehicle in Subjec [NCT00421993]	Phase 3	1,670 participants (Actual)	Interventional	2006-10-31	Completed
National Clinical Trial, Phase III, Monocentric, Randomized, Open, Controlled, Parallel Study to Assess the Non-inferiority of Dalap Duo® Product (0,1% Adapalene and 2,5% Benzoyl Peroxide Gel Cream) Compared to Epiduo® (0,1% Adapalene and 2,5% Benzoyl Per [NCT02716090]	Phase 3	0 participants (Actual)	Interventional		Withdrawn(stopped due to Due to budget limitations, the company decided to withdraw this study.)
Two-week Study to Determine and Compare the Tolerance and Irritation Potential of Topical Antibiotic and Benzoyl Peroxide to Benzoyl Peroxide and Adapalene Topical Gel Acne Medications [NCT00926367]	Phase 4	52 participants (Actual)	Interventional	2009-05-31	Completed
Two-week Study to Determine and Compare the Tolerance and Irritation Potential of Duac® Topical Gel (Clindamycin 1% and Benzoyl Peroxide 5%) to ACANYA™ Gel (Clindamycin Phosphate 1.2% and Benzoyl Peroxide 2.5%) Topical Acne Medications [NCT01015638]	Phase 4	36 participants (Actual)	Interventional	2009-08-31	Completed
[NCT00663286]	Phase 3	1,399 participants (Actual)	Interventional	2006-10-31	Completed
A Multi-center, Randomized, Double-blind, Vehicle-Controlled, Phase 2 Study of the Safety and Efficacy of Benzoyl Peroxide/Clindamycin Gel and Tazarotene Cream When Used in Combination in the Treatment of Acne Vulgaris [NCT00713609]	Phase 2	591 participants (Actual)	Interventional	2008-06-30	Completed
A Double Blind Randomised Comparison of Nadifloxacin 1% Cream Alone and Nadifloxacine %1 Cream With Benzoyl Peroxide 5% Solution in the Treatment of Mild to Moderate Facial Acne Vulgaris [NCT00869492]	Phase 3	90 participants (Anticipated)	Interventional	2008-08-31	Active, not recruiting
A Multi Center Double Blind Randomized Placebo Controlled Parallel Group Study Comparing Clindamycin and Benzoyl Peroxide Gel 1.2%/3.75% to Onexton™ Gel and Both Active Treatments to a Placebo Control in the Treatment of Acne Vulgaris [NCT02578043]	Phase 1	844 participants (Actual)	Interventional	2015-04-30	Completed
Can Benzoyl Peroxide Decrease the Burden of Cutibacterium Acnes in Primary Spine and Shoulder Surgery? Prospective Randomized Study [NCT05355844]		200 participants (Anticipated)	Interventional	2022-05-31	Not yet recruiting
Comparing Efficacy of Azithromycin and Probiotics for Treatment of Acne Vulgaris [NCT05629468]	Phase 3	75 participants (Actual)	Interventional	2021-10-15	Completed
A Phase 3, Randomized, Double-blind, Multi-dose Study to Evaluate the Safety and Efficacy of 5% Dapsone Topical Gel, (DTG 5%) When Co-administered With Vehicle Control, Adapalene Gel 0.1% or Benzoyl Peroxide Gel 4% in the Treatment of Acne Vulgaris. [NCT00151541]	Phase 3	301 participants (Actual)	Interventional	2005-02-28	Completed
Evaluation of the Efficacy and Tolerance of Formula 609613 37 in Acneic Patients as an Adjunct to and in Addition to 5% Benzoyl Peroxide for 6 Months [NCT05469880]		100 participants (Actual)	Interventional	2009-10-21	Completed
The Pulsed Dye Laser as an Adjuvant Treatment Modality in Acne Vulgaris - a Randomized Controlled Single Blinded Trial [NCT01052246]		80 participants (Actual)	Interventional	2008-10-31	Completed
A Multicenter, Double-Blind, Randomized, Vehicle-Controlled, Parallel-Group Study Comparing Adapalene and Benzoyl Peroxide Topical Gel 0.1%/2.5% (Actavis Mid-Atlantic LLC) To Epiduo™ (Adapalene and Benzoyl Peroxide) Gel 0.1%/2.5% (Galderma Laboratories, L [NCT01501799]		885 participants (Actual)	Interventional	2011-07-31	Completed
Two-week Study to Determine and Compare the Tolerance and Irritation Potential of Clindamycin and Benzoyl Peroxide to Dapsone Gel Topical Acne Medications [NCT00964366]	Phase 4	53 participants (Actual)	Interventional	2009-07-31	Completed
Efficacy and Safety of Adapalene 0.3%/Benzoyl Peroxide 2.5% Gel Plus Doxycycline in Severe Inflammatory Acne (Non-Nodulocystic) Subjects [NCT02899000]	Phase 4	186 participants (Actual)	Interventional	2016-07-29	Completed
A Clinical Assessment of the Use of RETIN-A MICRO (Tretinoin Gel) Microsphere, 0.04% in a Pump Dispenser and a 5% Benzoyl Peroxide Wash Used in the Morning Compared to the Use of RETIN-A MICRO 0.04% Pump Nightly and a 5% Benzoyl Peroxide Wash in the Morni [NCT00907257]	Phase 4	247 participants (Actual)	Interventional	2009-02-28	Completed
A Pilot Study to Evaluate the Efficacy of Fixed Dose Combination Clindamycin Phosphate 1.2%/Tretinoin 0.025% Gel Alone Versus Fixed Dose Combination Clindamycin Phosphate 1.2%/Tretinoin 0.025% Gel Plus Benzoyl Peroxide 6% Foaming Cloths in the Treatment o [NCT01422785]	Phase 4	40 participants (Anticipated)	Interventional	2011-07-31	Recruiting
Dermal Safety Study of GSK2585823 (Clindamycin 1%-Benzoyl Peroxide 3% Gel) With Healthy Japanese Male and Female Subjects [NCT01428466]	Phase 1	20 participants (Actual)	Interventional	2010-11-18	Completed
"A Comparative Clinical Evaluation of the Efficacy of Topical Adapalene, Benzoyl Peroxide Gel, Oral Lactobacillus Rhamnosus, D-chiro-inositol, Inulin Capsule, and Their Fixed Combination in Mild to Moderate Acne Vulgaris Patients." [NCT05855629]		59 participants (Actual)	Interventional	2022-02-18	Active, not recruiting
Assessment of Subjects' Efficacy and Experiences Using Adapalene BPO Gel in the Treatment of Acne Vulgaris [NCT01209949]	Phase 4	30 participants (Actual)	Interventional	2010-10-31	Completed
Triple Prevention Against Cutibacterium Acnes Using Benzoyl Peroxide Preparation in Addition to Pre-operative Cutaneous and Subcutaneous Iodine in Shoulder Surgery; a Single-blinded, Randomized, Controlled Trial. [NCT05701475]		156 participants (Anticipated)	Interventional	2023-02-28	Not yet recruiting
Randomized Study Comparing the Efficacy and Tolerance of a Lipophilic Hydroxy Acid Derivative of Salicylic Acid and 5% Benzoyl Peroxide in the Treatment of Facial Acne Vulgaris [NCT00624676]		80 participants (Actual)	Interventional	2006-01-31	Completed
An Investigator-Blind, Phase 4 Study Assessing the Facial Irritation Potential of Two Acne Treatment Products Using A Split-Face Model [NCT00919191]	Phase 4	26 participants (Actual)	Interventional	2009-04-30	Completed
Cutibacterium Acnes Persists Despite Topical Clindamycin and Benzoyl Peroxide [NCT03257202]	Phase 2	12 participants (Actual)	Interventional	2017-09-11	Completed
A Randomized Split-Face Controlled Trial Comparing Efficacy of 2940 Nanometer Er:YAG Laser to 2.5% BP Gel for the Treatment of Inflammatory Acne [NCT01472900]		25 participants (Anticipated)	Interventional	2010-10-31	Completed
A Long-term Safety and Efficacy Study of a Fixed Combination of Adapalene 0.1% and Benzoyl Peroxide 2.5% (Adapalene and Benzoyl Peroxide Topical Gel) Gel in Subjects With Acne Vulgaris [NCT00446043]	Phase 3	452 participants (Actual)	Interventional	2004-02-17	Completed
A Split-face, Paired-comparison Pilot Study to Evaluate the Safety and Efficacy of Topical Benzoyl Peroxide 2.5% Cream Alone Versus Benzoyl Peroxide 2.5% Cream Plus Moisturizing Lotion for Mild to Moderate Acne Vulgaris [NCT00558831]		11 participants (Actual)	Interventional	2007-10-31	Completed
A Split-face, Paired-comparison, Pilot Study to Evaluate Safety and Efficacy of Two Topical Benzoyl Peroxide 10.0% Creams for Mild to Moderate Acne Vulgaris [NCT00787943]		10 participants (Actual)	Interventional	2008-05-31	Completed
A Long Term Study of GK530G in Subjects With Acne Vulgaris [NCT01910064]	Phase 3	436 participants (Actual)	Interventional	2013-05-31	Completed
Epiduo in the Long-term Treatment of Moderate to Severe Acne With or Without Concomitant Medication [NCT01618773]		6,036 participants (Actual)	Observational	2012-06-30	Completed
Measuring Adherence in Subjects With Acne Vulgaris in a Clinic Population Subtitle: Topical Benzoyl Peroxide for Acne [NCT00658112]	Phase 4	20 participants (Actual)	Interventional	2006-07-31	Completed
Multimodal Optical Imaging for Pretreatment Evaluation for Cutaneous Microparticle Delivery [NCT03573115]		16 participants (Actual)	Interventional	2018-01-04	Completed
A Multi-Center, Double-Blind, Randomized, Placebo Controlled, Parallel-Group Study Comparing Adapalene and Benzoyl Peroxide Gel 0.1%/2.5% (Taro Pharmaceuticals Inc.) to Epiduo® (Galderma Laboratories, L.P., Adapalene and Benzoyl Peroxide Gel 0.1%/2.5%) an [NCT01742637]	Phase 1	2,008 participants (Actual)	Interventional	2012-10-31	Completed
A Multicenter, Double-Blind, Randomized, Vehicle-Controlled, Parallel-Group Study Comparing Taro Pharmaceutical Inc.'s Clindamycin Phosphate and Benzoyl Peroxide Gel, 1.2%/2.5% to the Reference Listed Acanya® (Clindamycin Phosphate and Benzoyl Peroxide)Ge [NCT01769235]	Phase 1	1,215 participants (Actual)	Interventional	2012-11-30	Completed
A Randomized, Double-Blind, Multiple-Site, Placebo-Controlled, Parallel Design Study Comparing Clindamycin 1%/Benzoyl Peroxide 5% Topical Gel (Taro Pharmaceuticals Inc.) to Duac® Topical Gel Clindamycin 1%/Benzoyl Peroxide 5% (Stiefel) in the Treatment of [NCT01769664]	Phase 1	650 participants (Actual)	Interventional	2012-09-30	Completed
A Multicenter, Double-blind, Randomized, Vehicle-controlled, Parallel-group Study Comparing Clindamycin Phosphate and Benzoyl Peroxide Gel and Acanya® 1.2%/2.5% and Both Active Treatments to Vehicle Control for Treating Acne Vulgaris [NCT01788384]	Phase 3	708 participants (Actual)	Interventional	2012-07-31	Completed
A Multi-Center, Double-Blind, Randomized, Vehicle-Controlled, Parallel-Group Study to Compare Perrigo Israel Pharmaceuticals, Ltd., Clindamycin 1%/Benzoyl Peroxide 5% Topical Gel to a Comparator Clindamycin / Benzoyl Peroxide Topical Gel, and Both Active [NCT01138514]	Phase 3	1,555 participants (Actual)	Interventional	2009-10-31	Completed
[NCT02515305]	Phase 3	890 participants (Actual)	Interventional	2015-07-31	Completed
[NCT01231334]	Phase 4	286 participants (Actual)	Interventional	2010-08-31	Completed
A Pilot Study to Evaluate the Safety and Tolerability of CeraVe® Lotion Followed by Fixed Dose Clindamycin Phosphate 1.2% / Benzoyl Peroxide 2.5% Gel in the Morning in Combination With CeraVe® Lotion Followed by Tretinoin 0.05% Gel in the Evening for the [NCT01448733]	Phase 4	20 participants (Actual)	Interventional	2011-07-31	Active, not recruiting
A Novel Method for Improving Acne Outcomes [NCT01176955]		20 participants (Actual)	Interventional	2009-05-31	Completed
A Multi-center, Randomized, Vehicle-controlled, Double-blind, Study to Evaluate the Safety and Efficacy of Epiduo® (Adapalene and Benzoyl Peroxide) Gel 0.1%/2.5% Administered Once Daily for the Treatment of Subjects 9 to 11 Years of Age With Acne Vulgaris [NCT01138735]	Phase 4	285 participants (Actual)	Interventional	2010-06-30	Completed
Exploratory Study to Evaluate the Efficacy and Safety of CD07223 1.5% Gel and 0.5% Gel in Subjects With Acne [NCT01106807]	Phase 2	73 participants (Actual)	Interventional	2010-04-30	Completed
A Clinical Trial Investigating the Effects of Acleara Needle Insert on Acne Vulgaris [NCT01677221]		30 participants (Actual)	Interventional	2012-07-31	Completed
Efficacy of a Handheld Heat Based Device for the Spot Treatment of Mild to Moderate Acne Vulgaris: A Controlled Study to Determine Time to Resolution of Individual Inflammatory Lesions Using an Over-the-counter Acne Heat Device. [NCT01613924]	Phase 4	0 participants (Actual)	Interventional	2013-07-31	Withdrawn(stopped due to Lack of funding and resources)
A Multi-Center, Double-Blind, Randomized, Vehicle-Controlled, Parallel-Group Study to Compare Perrigo Israel Pharmaceuticals, Ltd. Clindamycin Phosphate and Benzoyl Peroxide Topical Gel 1.2%/2.5% to Acanya® Topical Gel (Clindamycin Phosphate and Benzoyl P [NCT01796665]	Phase 3	1,180 participants (Actual)	Interventional	2012-02-29	Completed
[NCT02525549]	Phase 3	903 participants (Actual)	Interventional	2011-12-31	Completed
A Randomized, Double-blinded Study to Evaluate the Ability of an Acne Treatment Product to Produce Visible Improvements in Acne Lesions Over a 5 Day Period of Once-daily Use [NCT02052752]	Phase 4	90 participants (Actual)	Interventional	2014-02-28	Completed
Adjusting Skin Prep to Decrease Risk of P. Acnes Related Shoulder Infection [NCT02510144]		80 participants (Actual)	Interventional	2015-08-31	Completed
A Multi-Center, Randomized, Double-Blind, Parallel-Group Study to Demonstrate the Efficacy and Safety of Adapalene/Benzoyl Peroxide Topical Gel Compared With Adapalene Topical Gel, 0.1%; Benzoyl Peroxide Topical Gel, 2.5% and Topical Gel Vehicle in Subjec [NCT00422240]	Phase 3	1,656 participants (Anticipated)	Interventional	2006-06-30	Completed
Multi-Center, Double-Blind, Randomized, Vehicle-Controlled, Parallel-Group Study to Compare Perrigo's Adapalene/BP Gel to Galderma's Epiduo (Adapalene/BP) Gel, and Both Treatments to a Vehicle Control in the Treatment of Acne Vulgaris [NCT03393494]	Phase 3	825 participants (Actual)	Interventional	2017-12-13	Completed
[NCT00377000]	Phase 4	60 participants	Interventional	2005-11-30	Completed
A Multicenter, Randomized, Double-blinded, Vehicle-controlled Parallel Group Efficacy and Safety Study of 2 Different Concentrations of CD1579 Gels Versus Vehicle in the Treatment of Acne Vulgaris. [NCT02073461]	Phase 2	236 participants (Actual)	Interventional	2014-03-31	Completed
Benzaknen® 5% Gel in Combination With Dermotivin® Soft Liquid Soap and Non-comedogenic Cetaphil® Dermacontrol Moisturizer SPF30 in the Treatment of Mild-to-moderate Acne Vulgaris [NCT02589405]	Phase 4	50 participants (Actual)	Interventional	2015-08-31	Completed
Cutibacterium Dermal Colonization: Implications for Total Hip Arthroplasty [NCT03849885]	Phase 4	496 participants (Anticipated)	Interventional	2019-02-02	Recruiting
Epiduo® (Adapalene and Benzoyl Peroxide) Gel 0.1%/2.5% Pump, Cetaphil® DermaControl™ Moisturizer SPF 30, and Cetaphil® DermaControl™ Foam Wash Regimen in Student Athletes With Mild to Moderate Acne Vulgaris [NCT02249104]	Phase 4	28 participants (Actual)	Interventional	2014-08-31	Completed
Decreasing Proprionbacterium Acne Skin Colonization Prior to Arthroscopic Shoulder Surgery [NCT02219776]		100 participants (Actual)	Interventional	2015-09-30	Completed
An Open-Label, 12-Week Study to Evaluate the Efficacy and Safety of the Acne System (Benzoyl Peroxide 2.5%, Salicylic Acid 0.5%) in Subjects With Acne [NCT01446237]		125 participants (Actual)	Interventional	2011-06-01	Completed
A Study of Efficacy of Benzoyl Peroxide Regimens in Treatment of Unpleasant Foot Odor [NCT04000347]	Phase 4	0 participants (Actual)	Interventional	2019-06-26	Withdrawn(stopped due to Due to covid 19 outbreaks, the study are suspended.)
U0289-404: An Evaluator Blinded, 8 Week, Split Face Study to Evaluate and Compare the Efficacy and Tolerability of MAXCLARITYII and MURAD in Subjects With Acne [NCT02524665]	Phase 4	20 participants (Actual)	Interventional	2009-09-30	Completed
Efficacy and Safety Comparison of Adapalene 0.1% / Benzoyl Peroxide 2.5% Gel Versus Adapalene 0.1% / Benzoyl Peroxide 2.5% Gel Vehicle Gel as a 6-month Acne Maintenance Treatment [NCT00687908]	Phase 3	243 participants (Actual)	Interventional	2008-11-30	Completed
Epiduo® (Adapalene and Benzoyl Peroxide) Gel 0.1%/2.5% Pump Cetaphil® DermaControl™ Moisturizer SPF 30, and Cetaphil® DermaControl™ Foaming Wash Regimen in Patients With Mild to Moderate Acne Vulgaris [NCT01951417]	Phase 4	81 participants (Actual)	Interventional	2013-10-31	Completed
Study STF115288, a Clinical Confirmation Study of GI148512 (Benzoyl Peroxide 3% Gel) in the Treatment of Acne Vulgaris in Japanese Subjects.- A Multicenter, Randomized, Double-blinded, Vehicle-controlled, Parallel-group Study - [NCT01400932]	Phase 3	360 participants (Actual)	Interventional	2011-07-31	Completed
A Phase 3 Multi-Center, Double-Blind, Randomized, Vehicle-Controlled Study of S5G4T-1 in the Treatment of Papulopustular Rosacea [NCT03564119]	Phase 3	372 participants (Actual)	Interventional	2018-06-21	Completed
A Randomized, Double-blind, Multicentric, Parallel-group, Active and Placebo Controlled, Three Arm Clinical Study to Compare the Efficacy and Safety of Clindamycin Phosphate 1.2% / Benzoyl Peroxide 5% Gel (of Cadila Healthcare Limited, India) Versus DUAC® [NCT02005666]	Phase 3	850 participants (Actual)	Interventional	2013-11-30	Completed
Evaluation of the Effectiveness of Epiduo® Gel (Adapalene 0.1% / Benzoyl Peroxide 2.5% Gel) in Reducing Antibiotic Sensitive and Resistant Strains of P Acnes [NCT00907101]	Phase 4	30 participants (Actual)	Interventional	2009-06-30	Completed
Factors Affecting Medication Adherence to Topical Acne Medications: a Single-center, Prospective Study Evaluating the Adherence and Patient Satisfaction to Single and Multiple Topical Acne Medications [NCT05582434]	Early Phase 1	72 participants (Anticipated)	Interventional	2023-12-31	Not yet recruiting
Profiling the Skin Microbiome in Response to Altreno in Acne Patients [NCT04548349]	Phase 4	37 participants (Actual)	Interventional	2021-04-23	Completed
A Phase 3 Multi-Center, Double-Blind, Randomized, Vehicle-Controlled Study of S5G4T-1 in the Treatment of Papulopustular Rosacea [NCT03448939]	Phase 3	361 participants (Actual)	Interventional	2018-06-18	Completed
A Multi-Center, Open-Label, Long-Term Safety Study of S5G4T-1 to Evaluate the Safety of S5G4T-1 in Papulopustular Rosacea Patients [NCT03564145]	Phase 3	547 participants (Actual)	Interventional	2018-09-12	Terminated(stopped due to Per protocol, the Sponsor could terminate the study once 300 participants completed a total of 28 weeks of treatment and 100 participants completed a total of 52 weeks.)
The Effect of Pretreatment for Propionibacterium Acnes on Surgical Site Burden in Shoulder Arthroplasty; a Pilot Study [NCT04112407]		120 participants (Actual)	Interventional	2019-01-10	Completed
[NCT02651220]	Phase 3	1,001 participants (Actual)	Interventional	2015-11-30	Completed
A Multicenter, Randomized, Double-blinded, Active-controlled Parallel Group Efficacy and Safety Study of GK530G Versus CD0271 0.1% Gel and CD1579 2.5% Gel in the Treatment of Acne Vulgaris. [NCT02073448]	Phase 3	417 participants (Actual)	Interventional	2014-03-31	Completed
Effect of Sample Medication Use and Application Instructions on Adherence to and Efficacy of Treatment of Patients With Mild to Moderate Acne With Epiduo(R) Gel [NCT01504204]	Phase 4	20 participants (Actual)	Interventional	2011-12-31	Completed
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multiple-Site Study to Evaluate the Therapeutic Equivalence of a Generic Clindamycin 1%/Benzoyl Peroxide 5% Topical Gel (Glenmark Generics, Ltd) to the Marketed Product BenzaClin® Topical Gel [NCT02465632]	Phase 3	1,100 participants (Actual)	Interventional	2015-04-30	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Trial	Outcome
NCT00421993 (6) [back to overview]	Percent Change in Noniflammatory Lesion Counts
NCT00421993 (6) [back to overview]	Percent Change in Total Lesion Counts
NCT00421993 (6) [back to overview]	Success Rate on the Investigator's Global Assessment
NCT00421993 (6) [back to overview]	Percent Change in Inflammatory Lesion Counts
NCT00421993 (6) [back to overview]	Changes in Inflammatory Lesion Counts
NCT00421993 (6) [back to overview]	Changes in Noninflammatory Lesion Counts
NCT00446043 (7) [back to overview]	Number of Participant With Adverse Event (AE) and Serious Adverse Event (SAE)
NCT00446043 (7) [back to overview]	Number of Participants With Local Tolerability Assessment For Dryness
NCT00446043 (7) [back to overview]	Percent Change From Baseline in Inflammatory, Noninflammatory and Total Lesion Count at Month 12 LOCF
NCT00446043 (7) [back to overview]	Number of Participants With Clinically Significant Abnormal Laboratory Parameters
NCT00446043 (7) [back to overview]	Number of Participants With Local Tolerability Assessment For Erythema
NCT00446043 (7) [back to overview]	Number of Participants With Local Tolerability Assessment For Scaling
NCT00446043 (7) [back to overview]	Number of Participants With Local Tolerability Assessment For Stinging/Burning
NCT00558831 (1) [back to overview]	Subject Reported Change From Baseline Scale
NCT00658112 (1) [back to overview]	Adherence
NCT00671749 (7) [back to overview]	Worst Post Baseline Tolerability Assessment - Scaling
NCT00671749 (7) [back to overview]	Worst Post Baseline Tolerability Assessment - Erythema
NCT00671749 (7) [back to overview]	Worst Post Baseline Tolerability Assessment - Dryness
NCT00671749 (7) [back to overview]	Worst Post Baseline Tolerability Assessment - Burning/Stinging
NCT00671749 (7) [back to overview]	Percent Change From Baseline in Total Lesion Counts
NCT00671749 (7) [back to overview]	Global Severity Assessment Success
NCT00671749 (7) [back to overview]	Global Assessment of Improvement From Baseline
NCT00687908 (5) [back to overview]	Investigator Global Assessment (IGA) Maintenance Success at Week 24
NCT00687908 (5) [back to overview]	Maintenance Success for Non-inflammatory Lesions at Week 24
NCT00687908 (5) [back to overview]	Percent of Subjects With Adverse Events
NCT00687908 (5) [back to overview]	Maintenance Success for Total Lesions at Week 24
NCT00687908 (5) [back to overview]	Maintenance Success for Inflamatory Lesions at Week 24
NCT00713609 (4) [back to overview]	Proportion of Participants With an ISGA Score of 0 or 1 at Week 12
NCT00713609 (4) [back to overview]	Percent Change From Baseline to Week 12 in Each of 3 Lesion Counts (Total, Inflammatory, and Non-inflammatory)
NCT00713609 (4) [back to overview]	Proportion of Participants With a Minimum 2-grade Improvement in the Investigator's Static Global Assessment (ISGA) Score From Baseline to Week 12
NCT00713609 (4) [back to overview]	Absolute Change in Lesion Counts (Total, Inflammatory, and Non-inflammatory) From Baseline to Week 12
NCT00776919 (14) [back to overview]	Mean Percent Change From Baseline to Week 12 in Lesion Counts (Total, Inflammatory, and Non-inflammatory)
NCT00776919 (14) [back to overview]	Number of Participants Who Had an ISGA Score of 0 or 1 at Week 12
NCT00776919 (14) [back to overview]	Mean Change From Baseline to Weeks 2, 4, 8, and 12 in Itching and Burning/Stinging
NCT00776919 (14) [back to overview]	Mean Change From Baseline to Weeks 2, 4, 8, and 12 in Erythema, Dryness, and Peeling
NCT00776919 (14) [back to overview]	Mean Change From Baseline to Week 12 in Systolic and Diastolic Blood Pressure
NCT00776919 (14) [back to overview]	Number of Participants With Improvement of at Least 2 Grades in the Investigator's Static Global Assessment (ISGA) Score From Baseline to Week 12
NCT00776919 (14) [back to overview]	Mean Duration of Study Product Use
NCT00776919 (14) [back to overview]	Mean Change From Baseline to Week 12 in Total Lesion Counts
NCT00776919 (14) [back to overview]	Mean Change From Baseline to Week 12 in Temperature
NCT00776919 (14) [back to overview]	Mean Change From Baseline to Week 12 in Pulse Rate
NCT00776919 (14) [back to overview]	Number of Participants Who Had a Subject Global Assessment (SGA) Score of 0 or 1 at Week 12
NCT00776919 (14) [back to overview]	Mean Change From Baseline (BL) to Week 12 in Inflammatory Lesion Counts
NCT00776919 (14) [back to overview]	Number of Participants Reporting the Indicated Treatment-emergent Adverse Events (AEs) Resulting in Study Product Discontinuation
NCT00776919 (14) [back to overview]	Mean Change From Baseline to Week 12 in Non-inflammatory Lesion Counts
NCT00787943 (1) [back to overview]	Number of Inflammatory Lesions (Papules and Pustules)
NCT00837213 (8) [back to overview]	Percent Change in Total Acne Lesion Counts From Baseline to Week 16
NCT00837213 (8) [back to overview]	Percent Change in Total Lesions (Chest and Back) From Baseline to Week 12
NCT00837213 (8) [back to overview]	Change in Investigator Global Assessment (IGA)
NCT00837213 (8) [back to overview]	Percentage of Particpants With IGA Score at Week 16
NCT00837213 (8) [back to overview]	Percent (%) Change in Inflammatory Lesion Counts (Chest and Back) From Baseline to Week 12
NCT00837213 (8) [back to overview]	Percent (%) Change in Non-inflammatory Acne Lesions From Baseline to Week 16.
NCT00837213 (8) [back to overview]	Percent Change in Inflammatory Acne Lesions From Baseline to Week 16
NCT00837213 (8) [back to overview]	Percent Change in Non-inflammatory Lesions (Chest and Back) From Baseline to Week 12
NCT00887484 (44) [back to overview]	Erythema (Redness)
NCT00887484 (44) [back to overview]	Inflammatory Acne Lesion Counts
NCT00887484 (44) [back to overview]	Investigators Static Global Assessment
NCT00887484 (44) [back to overview]	Quality of Life Questionnaire - Global Score
NCT00887484 (44) [back to overview]	Quality of Life Questionnaire - Functional Domain
NCT00887484 (44) [back to overview]	Quality of Life Questionnaire - Emotional Domain
NCT00887484 (44) [back to overview]	Product Acceptability and Preference Questionnaire - Which Study Product is Subject More Satisfied With? at Weeks 1 and 2
NCT00887484 (44) [back to overview]	Product Acceptability and Preference Questionnaire - Use of Study Product if Choice to Continue Acne Treatment at Week 8
NCT00887484 (44) [back to overview]	Product Acceptability and Preference Questionnaire - Use of Study Product if Choice to Continue Acne Treatment at Week 1 and 2
NCT00887484 (44) [back to overview]	Product Acceptability and Preference Questionnaire - Severity of Scaling at Weeks 1 and 2
NCT00887484 (44) [back to overview]	Product Acceptability and Preference Questionnaire - Severity of Redness at Weeks 1 and 2
NCT00887484 (44) [back to overview]	Product Acceptability and Preference Questionnaire - Severity of Itching at Weeks 1 and 2
NCT00887484 (44) [back to overview]	Product Acceptability and Preference Questionnaire - Severity of Dryness at Weeks 1 and 2
NCT00887484 (44) [back to overview]	Product Acceptability and Preference Questionnaire - Severity of Burning at Weeks 1 and 2
NCT00887484 (44) [back to overview]	Product Acceptability and Preference Questionnaire - Overall Satisfaction of Study Product at Weeks 1 and 2
NCT00887484 (44) [back to overview]	Product Acceptability and Preference Questionnaire - Feeling of Hydrated and Moisturized Skin at Weeks 1 and 2
NCT00887484 (44) [back to overview]	Product Acceptability and Preference Questionnaire - Feeling of Hydrated and Moisturized Skin at Week 8
NCT00887484 (44) [back to overview]	Product Acceptability and Preference Questionnaire - Compliance at Week 8
NCT00887484 (44) [back to overview]	Product Acceptability and Preference Questionnaire - Decrease of Acne Breakouts by Study Products at Weeks 1 and 2
NCT00887484 (44) [back to overview]	Product Acceptability and Preference Questionnaire - Compliance at Weeks 1 and 2
NCT00887484 (44) [back to overview]	Product Acceptability and Preference Questionnaire - Comfort of Skin at Weeks 1 and 2
NCT00887484 (44) [back to overview]	Non-inflammatory Acne Lesion Counts
NCT00887484 (44) [back to overview]	Irritant/Allergic Contact Dermatitis
NCT00887484 (44) [back to overview]	Irritant/Allergic Contact Dermatitis
NCT00887484 (44) [back to overview]	Product Acceptability and Preference Questionnaire - Ease of Application of Product at Weeks 1 and 2
NCT00887484 (44) [back to overview]	Total Acne Lesion Counts
NCT00887484 (44) [back to overview]	Skindex-29 Quality of Life Questionnaire (QoL) - Symptomatic Domain
NCT00887484 (44) [back to overview]	Skin Peeling
NCT00887484 (44) [back to overview]	Skin Peeling
NCT00887484 (44) [back to overview]	Skin Dryness
NCT00887484 (44) [back to overview]	Skin Dryness
NCT00887484 (44) [back to overview]	Product Acceptability and Preference Questionnaire - Severity of Scaling at Week 8
NCT00887484 (44) [back to overview]	Product Acceptability and Preference Questionnaire - Comfort of Skin at Week 8
NCT00887484 (44) [back to overview]	Product Acceptability and Preference Questionnaire - Comparison of Study Products Used in the Past at Week 8
NCT00887484 (44) [back to overview]	Product Acceptability and Preference Questionnaire - Decrease of Acne Breakouts by Study Products at Week 8
NCT00887484 (44) [back to overview]	Product Acceptability and Preference Questionnaire - Ease of Application of Product at Week 8
NCT00887484 (44) [back to overview]	Product Acceptability and Preference Questionnaire - Ease of Use With Make-Up at Week 8
NCT00887484 (44) [back to overview]	Product Acceptability and Preference Questionnaire - Overall Satisfaction of Study Product at Week 8
NCT00887484 (44) [back to overview]	Product Acceptability and Preference Questionnaire - Severity of Burning at Week 8
NCT00887484 (44) [back to overview]	Product Acceptability and Preference Questionnaire - Severity of Dryness at Week 8
NCT00887484 (44) [back to overview]	Product Acceptability and Preference Questionnaire - Severity of Itching at Week 8
NCT00887484 (44) [back to overview]	Product Acceptability and Preference Questionnaire - Severity of Redness at Week 8
NCT00887484 (44) [back to overview]	Product Acceptability and Preference Questionnaire - Ease of Use Wtih Make-Up at Weeks 1 and 2
NCT00887484 (44) [back to overview]	Erythema (Redness)
NCT00907101 (5) [back to overview]	Worst Post Baseline Tolerability Assessment - Stinging/Burning
NCT00907101 (5) [back to overview]	Change From Baseline in Quantitative Bacteriology Measurements at Week 4
NCT00907101 (5) [back to overview]	Worst Post Baseline Tolerability Assessment - Dryness
NCT00907101 (5) [back to overview]	Worst Post Baseline Tolerability Assessment - Erythema
NCT00907101 (5) [back to overview]	Worst Post Baseline Tolerability Assessment - Scaling
NCT00907257 (3) [back to overview]	Measurement of Success
NCT00907257 (3) [back to overview]	Change From Baseline in Inflammatory and Non-Inflammatory Lesion Counts and Their Totals
NCT00907257 (3) [back to overview]	Change From Baseline in Total Facial Acne Lesion Count
NCT00907335 (6) [back to overview]	Change From Baseline in Total Non-inflammatory Lesion Count
NCT00907335 (6) [back to overview]	Measurement of Success 2
NCT00907335 (6) [back to overview]	Measurement of Success 3
NCT00907335 (6) [back to overview]	Measurement of Success 1
NCT00907335 (6) [back to overview]	Global Assessment
NCT00907335 (6) [back to overview]	Change From Baseline in Lesion Counts
NCT00919191 (2) [back to overview]	Self Assessment of Burning/Stinging and Itching
NCT00919191 (2) [back to overview]	Comparative Assessment of Facial Irritation and Cutaneous Effects.
NCT00926367 (18) [back to overview]	Skin Erythema (Redness)
NCT00926367 (18) [back to overview]	Skin Dryness
NCT00926367 (18) [back to overview]	Self Assessment of Texture (Roughness)
NCT00926367 (18) [back to overview]	Self Assessment of Stinging
NCT00926367 (18) [back to overview]	Self Assessment of Pain
NCT00926367 (18) [back to overview]	Self Assessment of Oiliness
NCT00926367 (18) [back to overview]	Self Assessment of Dryness
NCT00926367 (18) [back to overview]	Product Acceptability and Preference Questionnaire - How Compliant Were You With Applying the Study Product Each and Every Day?
NCT00926367 (18) [back to overview]	Self Assessment of Crusting
NCT00926367 (18) [back to overview]	Self Assessment of Burning
NCT00926367 (18) [back to overview]	Self Assessment of Blistering
NCT00926367 (18) [back to overview]	Product Acceptability and Preference Questionnaire - What Was Your Overall Satisfaction of the Study Product?
NCT00926367 (18) [back to overview]	Product Acceptability and Preference Questionnaire - Was the Study Product Easy to Use With Make-up?
NCT00926367 (18) [back to overview]	Product Acceptability and Preference Questionnaire - How do You Rate the Ease of Application of the Study Product?
NCT00926367 (18) [back to overview]	Product Acceptability and Preference Questionnaire - How do You Rate the Comfort of the Skin Where You Are Currently Treating With the Study Product?
NCT00926367 (18) [back to overview]	Skin Hydration
NCT00926367 (18) [back to overview]	Skin Moisture and Hydration
NCT00926367 (18) [back to overview]	Product Acceptability and Preference Questionnaire - Did You Feel That Your Skin Was Hydrated and Moisturized While You Were on Your Study Product?
NCT00952523 (1) [back to overview]	Facial Irritation and Cutaneous Effects
NCT00964223 (44) [back to overview]	Product Acceptability and Preference Questionnaire - Decrease of Acne Breakouts by Study Products
NCT00964223 (44) [back to overview]	Product Acceptability and Preference Questionnaire - Ease of Application of Product
NCT00964223 (44) [back to overview]	Product Acceptability and Preference Questionnaire - Ease of Use With Make-Up
NCT00964223 (44) [back to overview]	Product Acceptability and Preference Questionnaire - Overall Satisfaction of Study Product
NCT00964223 (44) [back to overview]	Product Acceptability and Preference Questionnaire - Severity of Burning
NCT00964223 (44) [back to overview]	Product Acceptability and Preference Questionnaire - Severity of Dryness
NCT00964223 (44) [back to overview]	Product Acceptability and Preference Questionnaire - Severity of Itching
NCT00964223 (44) [back to overview]	Product Acceptability and Preference Questionnaire - Severity of Redness
NCT00964223 (44) [back to overview]	Product Acceptability and Preference Questionnaire - Severity of Scaling
NCT00964223 (44) [back to overview]	Erythema (Redness) Score
NCT00964223 (44) [back to overview]	Erythema (Redness) Score
NCT00964223 (44) [back to overview]	Inflammatory Acne Lesion Counts
NCT00964223 (44) [back to overview]	Investigator Static Global Assessment Score
NCT00964223 (44) [back to overview]	Irritant/Allergic Contact Dermatitis Score
NCT00964223 (44) [back to overview]	Non-Inflammatory Acne Lesion Counts
NCT00964223 (44) [back to overview]	Product Acceptability and Preference Questionnaire - Comfort of Skin
NCT00964223 (44) [back to overview]	Product Acceptability and Preference Questionnaire - Compliance
NCT00964223 (44) [back to overview]	Product Acceptability and Preference Questionnaire - Compliance
NCT00964223 (44) [back to overview]	Product Acceptability and Preference Questionnaire - Decrease of Acne Breakouts by Study Products
NCT00964223 (44) [back to overview]	Product Acceptability and Preference Questionnaire - Ease of Application of Product
NCT00964223 (44) [back to overview]	Product Acceptability and Preference Questionnaire - Ease of Use With Make-Up
NCT00964223 (44) [back to overview]	Product Acceptability and Preference Questionnaire - Feeling of Hydrated and Moisturized Skin
NCT00964223 (44) [back to overview]	Product Acceptability and Preference Questionnaire - Feeling of Hydrated and Moisturized Skin
NCT00964223 (44) [back to overview]	Product Acceptability and Preference Questionnaire - Overall Satisfaction of Study Product
NCT00964223 (44) [back to overview]	Product Acceptability and Preference Questionnaire - Severity of Burning
NCT00964223 (44) [back to overview]	Product Acceptability and Preference Questionnaire - Severity of Dryness
NCT00964223 (44) [back to overview]	Product Acceptability and Preference Questionnaire - Severity of Itching
NCT00964223 (44) [back to overview]	Product Acceptability and Preference Questionnaire - Use of Study Product if Choice to Continue Acne Treatment
NCT00964223 (44) [back to overview]	Product Acceptability and Preference Questionnaire - Severity of Scaling
NCT00964223 (44) [back to overview]	Product Acceptability and Preference Questionnaire - Use of Study Product if Choice to Continue Acne Treatment
NCT00964223 (44) [back to overview]	Product Acceptability and Preference Questionnaire - Which Study Product is Subject More Satisfied With?
NCT00964223 (44) [back to overview]	Skin Dryness Score
NCT00964223 (44) [back to overview]	Skin Dryness Score
NCT00964223 (44) [back to overview]	Skin Peeling Score
NCT00964223 (44) [back to overview]	Skin Peeling Score
NCT00964223 (44) [back to overview]	Skindex-29 Quality of Life Questionnaire - Emotional Domain
NCT00964223 (44) [back to overview]	Skindex-29 Quality of Life Questionnaire - Functional Domain
NCT00964223 (44) [back to overview]	Skindex-29 Quality of Life Questionnaire - Global Score
NCT00964223 (44) [back to overview]	Skindex-29 Quality of Life Questionnaire - Symptomatic Domain
NCT00964223 (44) [back to overview]	Total Acne Lesion Counts
NCT00964223 (44) [back to overview]	Irritant/Allergic Contact Dermatitis Score
NCT00964223 (44) [back to overview]	Product Acceptability and Preference Questionnaire - Comparison of Study Products to Products Used in the Past
NCT00964223 (44) [back to overview]	Product Acceptability and Preference Questionnaire - Severity of Redness
NCT00964223 (44) [back to overview]	Product Acceptability and Preference Questionnaire - Comfort of Skin
NCT00964366 (5) [back to overview]	Skin Erythema (Redness)
NCT00964366 (5) [back to overview]	Skin Hydration
NCT00964366 (5) [back to overview]	Transepidermal Water Loss (TEWL)
NCT00964366 (5) [back to overview]	Skin Dryness
NCT00964366 (5) [back to overview]	Sebum Measurements
NCT01015638 (12) [back to overview]	Subject Assessment - Crusting
NCT01015638 (12) [back to overview]	Subject Assessment - Dryness
NCT01015638 (12) [back to overview]	Subject Assessment - Blistering
NCT01015638 (12) [back to overview]	Changes in the Skin Surface Hydration
NCT01015638 (12) [back to overview]	Erythema (Redness)
NCT01015638 (12) [back to overview]	Skin Dryness
NCT01015638 (12) [back to overview]	Skin Moisture and Hydration
NCT01015638 (12) [back to overview]	Subject Assessment - Oiliness
NCT01015638 (12) [back to overview]	Subject Assessment - Pain
NCT01015638 (12) [back to overview]	Subject Assessment - Roughness
NCT01015638 (12) [back to overview]	Subject Tolerability - Burning
NCT01015638 (12) [back to overview]	Subject Tolerability - Stinging
NCT01016977 (15) [back to overview]	Mean Change From Baseline in Itching at Weeks 1, 2, 4, 8, and 12
NCT01016977 (15) [back to overview]	Mean Change From Baseline in Oiliness at Weeks 1, 2, 4, 8, and 12
NCT01016977 (15) [back to overview]	Mean Change From Baseline in Peeling at Weeks 1, 2, 4, 8, and 12
NCT01016977 (15) [back to overview]	Mean Change From Baseline for the Functional Score of the Participant-completed Skindex-29 Quality of Life Questionnaire at Week 12
NCT01016977 (15) [back to overview]	Mean Change From Baseline for the Global Score of the Participant-completed Skindex-29 Quality of Life Questionnaire at Week 12
NCT01016977 (15) [back to overview]	Mean Change From Baseline in Erythema at Weeks 1, 2, 4, 8, and 12
NCT01016977 (15) [back to overview]	Mean Change From Baseline for the Symptomatic Score of the Participant-completed Skindex-29 Quality of Life Questionnaire at Week 12
NCT01016977 (15) [back to overview]	Number of Participants With at Least a Two-grade Improvement in ISGA Score From Baseline to Week 12
NCT01016977 (15) [back to overview]	Mean Change From Baseline in Burning/Stinging at Weeks 1, 2, 4, 8, and 12
NCT01016977 (15) [back to overview]	Mean Change From Baseline in Dryness at Weeks 1, 2, 4, 8, and 12
NCT01016977 (15) [back to overview]	Mean Change From Baseline in Inflammatory and Non-inflammatory Lesion Counts at Weeks 1, 2, 4, 8, and 12
NCT01016977 (15) [back to overview]	Mean Change From Baseline for the Emotional Score of the Participant-completed Skindex-29 Quality of Life Questionnaire at Week 12
NCT01016977 (15) [back to overview]	Overall Satisfaction With Study Product at Week 12
NCT01016977 (15) [back to overview]	Mean Change From Baseline in Total Lesion Count at Weeks 1, 2, 4, 8, and 12
NCT01016977 (15) [back to overview]	Mean Change From Baseline in Skin Overall Comfort at Weeks 1, 2, 4, 8, and 12
NCT01044264 (1) [back to overview]	Reduction of Inflammatory Lesions
NCT01138514 (3) [back to overview]	Number of Participant With Clinical Success on the Investigator's Global Assessment (IGA)
NCT01138514 (3) [back to overview]	Percent Change From Baseline in Inflammatory Lesions
NCT01138514 (3) [back to overview]	Percent Change From Baseline in Non-inflammatory Lesions
NCT01138735 (4) [back to overview]	Change From Baseline in Total Lesion Counts
NCT01138735 (4) [back to overview]	Change in Inflammatory Lesion Counts From Baseline
NCT01138735 (4) [back to overview]	Percent Change in Total Lesion Counts From Baseline
NCT01138735 (4) [back to overview]	Success Rate
NCT01176955 (4) [back to overview]	The Change (Dynamic Assessment) in the Acne Global Assessment From Baseline to End of Study.
NCT01176955 (4) [back to overview]	The Measured Adherence by the MEMS Cap in Relation to the Change (Dynamic Assessment) in the Acne Global Assessment.
NCT01176955 (4) [back to overview]	The Measured Adherence by the MEMS Cap in Relation to the Patient Reported Adherence Via the Internet Survey.
NCT01176955 (4) [back to overview]	The Change (Dynamic Assessment) From Baseline to End of Treatment in Lesion Counts.
NCT01209949 (3) [back to overview]	Number of Participants Who Were a Success (Subject's Global Assessment of 'Clear' or 'Almost Clear') at Week 12
NCT01209949 (3) [back to overview]	Number of Participants With Tolerability Assessments Resulting in an Adverse Event
NCT01209949 (3) [back to overview]	Percent Change From Baseline in Lesion Counts (Inflammatory, Non-inflammatory, and Total) at Week 12.
NCT01231334 (7) [back to overview]	Percentage of Participants Demonstrating a ≥ 1 Category Increase in Tolerability From Baseline at Week 12
NCT01231334 (7) [back to overview]	Change From Baseline in Global Acne Assessment Score (GAAS) at Week 12
NCT01231334 (7) [back to overview]	Percentage of Participants With at Least a One Point Decrease in the Global Acne Assessment Score (GAAS) at Week 12
NCT01231334 (7) [back to overview]	Percentage of Participants at Week 12 Having at Least a One Point Decrease in Overall Disease Severity
NCT01231334 (7) [back to overview]	Percent Change From Baseline in Total Lesion Count at Week 12
NCT01231334 (7) [back to overview]	Percent Change From Baseline in Inflammatory Lesion Counts at Week 12
NCT01231334 (7) [back to overview]	Percent Change From Baseline in Non-inflammatory Lesion Counts at Week 12
NCT01400932 (9) [back to overview]	Absolute Change From Baseline in Inflammatory Lesion (IL) Count and Non-inflammatory Lesion (NIL) Count to Weeks 1, 2, 4, 8, and 12
NCT01400932 (9) [back to overview]	Number of Participants Who Had a Minimum 2-grade Improvement in the Investigator's Static Global Assessment (ISGA) Score From Baseline to Week 12
NCT01400932 (9) [back to overview]	Absolute Change in Total Lesion Counts From Baseline to Week 12
NCT01400932 (9) [back to overview]	Mean Change From Baseline in Itching and Burning/Stinging Scores at Weeks 1, 2, 4, 8, 12/Withdrawal
NCT01400932 (9) [back to overview]	Percent Change From Baseline in Total, Inflammatory, and Non-inflammatory Lesion Counts to Weeks 1, 2, 4, 8, and 12
NCT01400932 (9) [back to overview]	Number of Participants Who Had an ISGA Score of 0 or 1 at Weeks 1, 2, 4, 8, and 12
NCT01400932 (9) [back to overview]	Number of Participants Who Had a Reduction in Total Lesions of at Least 50% From Baseline to Weeks 1, 2, 4, 8, and 12
NCT01400932 (9) [back to overview]	Mean Change From Baseline in Erythema, Dryness, and Peeling Scores at Weeks 1, 2, 4, 8, 12/Withdrawal
NCT01400932 (9) [back to overview]	Absolute Change in Total Lesion Counts From Baseline to Weeks 1, 2, 4, and 8
NCT01446237 (5) [back to overview]	Number of Participants With ISGA Score of 0 (Clear) or 1 (Almost Clear) at Each Study Visit
NCT01446237 (5) [back to overview]	Absolute Change in IL, NIL, and TL Count From Baseline to Each Study Visit
NCT01446237 (5) [back to overview]	Mean Change in ISGA From Baseline to Each Study Visit
NCT01446237 (5) [back to overview]	Mean Percent Changes in Inflammatory (IL), Non-inflammatory (NIL), and Total Lesion (TL) Counts From Baseline to Each Study Visit
NCT01446237 (5) [back to overview]	Number of Participants With a Minimum 2-grade Improvement of Investigator's Static Global Assessment (ISGA) From Baseline to Each Study Visit
NCT01504204 (3) [back to overview]	Change in Acne Global Assessment
NCT01504204 (3) [back to overview]	Change in Acne Lesion Count
NCT01504204 (3) [back to overview]	Adherence to Study Medication
NCT01796665 (3) [back to overview]	Clinical Success on Investigator's Global Evaluation
NCT01796665 (3) [back to overview]	Mean Percent Change in the Inflammatory (Papules and Pustules) Lesion Count
NCT01796665 (3) [back to overview]	Mean Percent Change in the Non-inflammatory (Open and Closed Comedones) Lesion Count
NCT01910064 (6) [back to overview]	Local Tolerability (Stinging/Burning)
NCT01910064 (6) [back to overview]	Local Tolerability (Dryness)
NCT01910064 (6) [back to overview]	Local Tolerability (Erythema)
NCT01910064 (6) [back to overview]	Local Tolerability (Pruritus)
NCT01910064 (6) [back to overview]	Local Tolerability (Scaling)
NCT01910064 (6) [back to overview]	Percent Changes From Baseline in Total Lesion Counts
NCT01951417 (8) [back to overview]	Inflammatory Lesions
NCT01951417 (8) [back to overview]	Scaling
NCT01951417 (8) [back to overview]	Non-inflammatory Lesions
NCT01951417 (8) [back to overview]	Subject Questionnaire
NCT01951417 (8) [back to overview]	Stinging/Burning
NCT01951417 (8) [back to overview]	Erythema
NCT01951417 (8) [back to overview]	Dryness
NCT01951417 (8) [back to overview]	Total Lesion Count
NCT02005666 (2) [back to overview]	Mean Percent Change From Baseline to Week 11 in the Non-inflammatory Lesion Count
NCT02005666 (2) [back to overview]	Mean Percent Change From Baseline to Week 11 (Study Day 77) for Inflammatory (Papules and Pustules) Lesions.
NCT02052752 (6) [back to overview]	To Assess the Change in Facial Skin Clarity for the 3% BPO Gel Test Product and Positive Control Relative to the Vehicle Gel
NCT02052752 (6) [back to overview]	To Assess the Change in Acne Lesion Redness (Erythema) for the 3% BPO Gel Test Product and Positive Control Relative to the Vehicle Gel.
NCT02052752 (6) [back to overview]	To Assess the Percentage Change in Acne Lesion Swelling (Height) for the 3% Benzoyl Peroxide Gel Test Product and Positive Control Relative to the Vehicle Gel.
NCT02052752 (6) [back to overview]	To Assess the Percentage Change in Acne Lesion Diameter (Size) for the 3% BPO Gel Test Product and Positive Control Relative to the Vehicle Gel.
NCT02052752 (6) [back to overview]	To Assess the Change in Perceptions of the Overall Appearance of Their Skin for the 3% BPO Gel Test Product and Positive Control Relative to the Vehicle Gel
NCT02052752 (6) [back to overview]	To Assess the Percentage Change in Acne Lesion Swelling (Height) of the Target Lesion for 3% Benzoyl Peroxide (BPO) Gel Test Product Relative to the Vehicle Gel After 4 Once-daily Applications.
NCT02073448 (7) [back to overview]	Percent Changes From Baseline in Total Lesion Counts
NCT02073448 (7) [back to overview]	Percent of Subjects With Adverse Events
NCT02073448 (7) [back to overview]	Local Tolerability (Dryness)
NCT02073448 (7) [back to overview]	Local Tolerability (Erythema)
NCT02073448 (7) [back to overview]	Local Tolerability (Pruritus)
NCT02073448 (7) [back to overview]	Local Tolerability (Scaling)
NCT02073448 (7) [back to overview]	Local Tolerability (Stinging/Burning)
NCT02073461 (7) [back to overview]	Local Tolerability (Dryness)
NCT02073461 (7) [back to overview]	Percent Changes From Baseline in Total Lesion Counts
NCT02073461 (7) [back to overview]	Local Tolerability (Erythema)
NCT02073461 (7) [back to overview]	Percent of Subjects With Adverse Events
NCT02073461 (7) [back to overview]	Local Tolerability (Stinging/Burning)
NCT02073461 (7) [back to overview]	Local Tolerability (Scaling)
NCT02073461 (7) [back to overview]	Local Tolerability (Pruritus)
NCT02249104 (6) [back to overview]	Percent Change From Baseline in Non-inflammatory Lesion Count
NCT02249104 (6) [back to overview]	Percent Change From Baseline in Inflammatory Lesion Count
NCT02249104 (6) [back to overview]	Mean Change From Baseline in Total Lesion Count
NCT02249104 (6) [back to overview]	Mean Change From Baseline in Non-inflammatory Lesion Count
NCT02249104 (6) [back to overview]	Mean Change From Baseline in Inflammatory Lesion Count
NCT02249104 (6) [back to overview]	Percent Change From Baseline in Total Lesion Count
NCT02465632 (2) [back to overview]	Mean Percent Change in the Number of Inflamed Lesions (Papules/Pustules)
NCT02465632 (2) [back to overview]	Mean Percent Change in the Number of Non-inflamed Lesions (Open and Closed Comedones)
NCT02510144 (2) [back to overview]	Surgical Site Infection That Requires Antibiotics
NCT02510144 (2) [back to overview]	Skin Swab and Culture With Colony Forming Units (CFUs)
NCT02515305 (2) [back to overview]	Mean Percent Change From Baseline in Non-inflammatory (Open and Closed Comedones) Lesions
NCT02515305 (2) [back to overview]	Mean Percent Change From Baseline in Inflammatory (Papules and Pustules) Lesions
NCT02524665 (6) [back to overview]	Change in Investigator Assessment of Tolerability (Erythema, Dryness and Peeling) From Baseline to Weeks 1, 2, 4 and 8.
NCT02524665 (6) [back to overview]	Change in Participant Assessment of Tolerability (Redness, Dryness, Burning, Itching and Scaling) From Baseline to Weeks 1, 2, 4 and 8.
NCT02524665 (6) [back to overview]	Mean Change in Investigator's Static Global Assessment (ISGA) From Baseline to Week 1, 2, 4 and 8
NCT02524665 (6) [back to overview]	Mean Percent Change in Inflammatory, Non-inflammatory and Total Lesion Counts From Baseline to Week 1, 2 and 4.
NCT02524665 (6) [back to overview]	Mean Percent Change in Inflammatory, Non-inflammatory and Total Lesion Counts From Baseline to Week 8.
NCT02524665 (6) [back to overview]	Percentage of Participant Who Improved by at Least One Grade on the ISGA
NCT02525549 (2) [back to overview]	Mean Percent Change From Baseline to Day 84 in Inflammatory (Papules and Pustules) Lesions
NCT02525549 (2) [back to overview]	Mean Percent Change From Baseline to Day 84 in Non-inflammatory (Open and Closed Comedones) Lesions
NCT02589405 (1) [back to overview]	Number of Participants Satisfied and Very Satisfied With Regimen
NCT02616614 (3) [back to overview]	Percent Change in the Inflammatory (Papules and Pustules) Lesion Counts
NCT02616614 (3) [back to overview]	Percent Change in the Non-Inflammatory (Open and Closed Comedomes) Lesion Counts
NCT02616614 (3) [back to overview]	Number of Subjects With Treatment Success at Week 12
NCT02651220 (3) [back to overview]	"Percentage of Patients With a Clinical Response of Clinical Success Using the Investigator's Global Assessment (IGA) at Week 12"
NCT02651220 (3) [back to overview]	Percent Change From Baseline to Week 12 in the Number of Inflamed Lesions.
NCT02651220 (3) [back to overview]	Percent Change From Baseline to Week 12 in the Number of Non-inflamed Lesions.
NCT02698436 (17) [back to overview]	Investigator Global Acne Assessment - Week 1
NCT02698436 (17) [back to overview]	Investigator Global Acne Assessment - Baseline
NCT02698436 (17) [back to overview]	Acne Lesion Counts Total Global Face - Week 8
NCT02698436 (17) [back to overview]	Acne Lesion Counts Total Global Face - Week 4
NCT02698436 (17) [back to overview]	Acne Lesion Counts Total Global Face - Week 2
NCT02698436 (17) [back to overview]	Acne Lesion Counts Total Global Face - Week 12
NCT02698436 (17) [back to overview]	Acne Lesion Counts Total Global Face - Week 1
NCT02698436 (17) [back to overview]	Acne Lesion Counts Total Global Face - Baseline
NCT02698436 (17) [back to overview]	Percent Change of Global Face Total Acne Lesion Count From Baseline to Week 8
NCT02698436 (17) [back to overview]	Percent Change of Global Face Total Acne Lesion Count From Baseline to Week 4
NCT02698436 (17) [back to overview]	Investigator Global Acne Assessment - Week 12
NCT02698436 (17) [back to overview]	Investigator Global Acne Assessment - Week 4
NCT02698436 (17) [back to overview]	Percent Change of Global Face Total Acne Lesion Count From Baseline to Week 1
NCT02698436 (17) [back to overview]	Percent Change of Global Face Total Acne Lesion Count From Baseline
NCT02698436 (17) [back to overview]	Investigator Global Acne Assessment - Week 8
NCT02698436 (17) [back to overview]	Investigator Global Acne Assessment - Week 2
NCT02698436 (17) [back to overview]	Percent Change of Global Face Total Acne Lesion Count From Baseline to Week 2
NCT02899000 (11) [back to overview]	Percent Change From Baseline in Non-Inflammatory Lesion Count
NCT02899000 (11) [back to overview]	Percent Change From Baseline in Inflammatory Lesion Count
NCT02899000 (11) [back to overview]	Number and Percent of Subjects With IGA Success
NCT02899000 (11) [back to overview]	Investigator's Evaluation: Number of Subjects Not Considered to be Oral Isotretinoin Candidates
NCT02899000 (11) [back to overview]	Change From Baseline in Total Lesion Count
NCT02899000 (11) [back to overview]	Change From Baseline in Non-Inflammatory Lesion Count
NCT02899000 (11) [back to overview]	Change From Baseline in Inflammatory Lesion Count
NCT02899000 (11) [back to overview]	Subject Assessment of Acne Improvement
NCT02899000 (11) [back to overview]	Change in Number of Inflammatory Lesions
NCT02899000 (11) [back to overview]	Number and Percent of Adverse Events
NCT02899000 (11) [back to overview]	Percent Change From Baseline in Total Lesion Count
NCT03122457 (2) [back to overview]	Adverse Event Severity
NCT03122457 (2) [back to overview]	PGA Score
NCT03257202 (1) [back to overview]	Number of Subjects With Positive Bacterial Growth Culture Per Treatment Arms
NCT03393494 (2) [back to overview]	Mean Percent Change From Baseline in the Open and Closed Comedones Lesion Count
NCT03393494 (2) [back to overview]	Mean Percent Change From Baseline in the Papules and Pustules Lesion Count
NCT03448939 (3) [back to overview]	Change From Baseline in Inflammatory Lesion Counts at Week 12
NCT03448939 (3) [back to overview]	Percent Change From Baseline in Inflammatory Lesion Counts at Week 12
NCT03448939 (3) [back to overview]	Percentage of Participants Achieving an IGA Score of Clear or Almost Clear From Baseline at Week 12
NCT03457636 (4) [back to overview]	Non-inflammatory Lesion Count
NCT03457636 (4) [back to overview]	IGA Score
NCT03457636 (4) [back to overview]	Investigator Global Assessment (IGA) Score
NCT03457636 (4) [back to overview]	Inflammatory Lesion Count
NCT03564119 (3) [back to overview]	Change From Baseline in Inflammatory Lesion Counts at Week 12
NCT03564119 (3) [back to overview]	Percentage of Participants Achieving an IGA Score of Clear or Almost Clear From Baseline at Week 12
NCT03564119 (3) [back to overview]	Percent Change From Baseline in Inflammatory Lesion Counts at Week 12
NCT03564145 (1) [back to overview]	Number of Participants With Treatment Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)
NCT03761784 (11) [back to overview]	Change From Baseline in Non-Inflammatory Lesion Counts on the Face at Week 12
NCT03761784 (11) [back to overview]	Percentage of Participants Achieving at Least a 4-Point Reduction on Item 5 (Embarrassment) of the Pre-Face
NCT03761784 (11) [back to overview]	Percentage of Participants Achieving at Least a 4-Point Reduction on Item 1 (Pimple) of the Patient-Reported Evaluation of Facial Acne (Pre-Face)
NCT03761784 (11) [back to overview]	Change From Baseline in Inflammatory Lesion Counts on the Face at Week 12
NCT03761784 (11) [back to overview]	Change From Baseline in Inflammatory Lesion Counts on the Face at Week 4
NCT03761784 (11) [back to overview]	Change From Baseline in Inflammatory Lesion Counts on the Face at Week 8
NCT03761784 (11) [back to overview]	Change From Baseline in Non-Inflammatory Lesion Counts on the Face at Week 4
NCT03761784 (11) [back to overview]	Change From Baseline in Non-Inflammatory Lesion Counts on the Face at Week 8
NCT03761784 (11) [back to overview]	Percent Change From Baseline in Inflammatory Lesion Counts on the Face at Week 12
NCT03761784 (11) [back to overview]	Percent Change From Baseline in Non-Inflammatory Lesion Counts on the Face at Week 12
NCT03761784 (11) [back to overview]	Percentage of Participants Achieving an IGA Score of Clear or Almost Clear and a Score ≥2 Grades Less Than Baseline
NCT03761810 (11) [back to overview]	Change From Baseline in Inflammatory Lesion Counts on the Face at Week 12
NCT03761810 (11) [back to overview]	Change From Baseline in Inflammatory Lesion Counts on the Face at Week 4
NCT03761810 (11) [back to overview]	Change From Baseline in Inflammatory Lesion Counts on the Face at Week 8
NCT03761810 (11) [back to overview]	Change From Baseline in Non-Inflammatory Lesion Counts on the Face at Week 12
NCT03761810 (11) [back to overview]	Change From Baseline in Non-Inflammatory Lesion Counts on the Face at Week 8
NCT03761810 (11) [back to overview]	Percent Change From Baseline in Inflammatory Lesion Counts on the Face at Week 12
NCT03761810 (11) [back to overview]	Percent Change From Baseline in Non-Inflammatory Lesion Counts on the Face at Week 12
NCT03761810 (11) [back to overview]	Percentage of Participants Achieving an IGA Score of Clear or Almost Clear and a Score ≥2 Grades Less Than Baseline
NCT03761810 (11) [back to overview]	Percentage of Participants Achieving at Least a 4-Point Reduction on Item 5 (Embarrassment) of the Pre-Face
NCT03761810 (11) [back to overview]	Change From Baseline in Non-Inflammatory Lesion Counts on the Face at Week 4
NCT03761810 (11) [back to overview]	Percentage of Participants Achieving at Least a 4-Point Reduction on Item 1 (Pimple) of the Patient-Reported Evaluation of Facial Acne (Pre-Face)
NCT04021524 (2) [back to overview]	Number of Quadrants on Culture Plate of Propionibacteria Growth - Specimens Taken Day of Surgery After At-Home Washes With Benzoyl Peroxide or Chlorhexidine Gluconate
NCT04021524 (2) [back to overview]	Number of Patients With a Positive Propionibacteria Swabs on Day of Surgery After At-Home Washes With Benzoyl Peroxide or Chlorhexidine Gluconate
NCT04300010 (4) [back to overview]	Median Colony Forming Units Per mL Treatment vs Control
NCT04300010 (4) [back to overview]	Percentage of Participants in Each Group With Positive C. Acnes Cultures
NCT04300010 (4) [back to overview]	Median Colony Forming Units (CFU) After Treatment
NCT04300010 (4) [back to overview]	Number of Participants With C. Acnes Bacterium Culture After Treatment
NCT05096312 (2) [back to overview]	Inflammatory Score
NCT05096312 (2) [back to overview]	Global Acne Grading System Score

Percent Change in Noniflammatory Lesion Counts

Percent Changes in Noninflammatory Lesion Counts equals (Week 12 count minus Baseline count) divided by Baseline count multiplied by 100 (NCT00421993)
Timeframe: at week 12

Intervention	Percent change (Mean)
Adapalene/Benzoyl Peroxide Gel	-55.6
Adapalene Gel	-46.0
Benzoyl Peroxide Gel	-44.1
Gel Vehicle	-32.3

Intervention	Percent change (Mean)
Adapalene/Benzoyl Peroxide Gel	-57.7
Adapalene Gel	-47.5
Benzoyl Peroxide Gel	-47.2
Gel Vehicle	-35.2

Intervention	Percentage of participants (Number)
Adapalene/Benzoyl Peroxide Gel	37.9
Adapalene Gel	21.8
Benzoyl Peroxide Gel	26.7
Gel Vehicle	17.9

Intervention	Percent change (Mean)
Adapalene/Benzoyl Peroxide Gel	-61.7
Adapalene Gel	-50.1
Benzoyl Peroxide Gel	-52.2
Gel Vehicle	-40.8

Intervention	Participants (Count of Participants)
	Participants (N) With At least one AE	Participants (N) With At Least one SAE
Adapalene/Benzoyl Peroxide	288	5

Intervention	Participants (Count of Participants)
	Baseline72323857				Week 172323857	Week 272323857	Month 172323857	Month 272323857	Month 472323857	Month 672323857	Month 872323857	Month 1072323857	Month 1272323857
	1=Mild	0=None	2=Moderate	3=Severe
Adapalene/Benzoyl Peroxide	385
Adapalene/Benzoyl Peroxide	65
Adapalene/Benzoyl Peroxide	2
Adapalene/Benzoyl Peroxide	195
Adapalene/Benzoyl Peroxide	190
Adapalene/Benzoyl Peroxide	35
Adapalene/Benzoyl Peroxide	264
Adapalene/Benzoyl Peroxide	152
Adapalene/Benzoyl Peroxide	12
Adapalene/Benzoyl Peroxide	1
Adapalene/Benzoyl Peroxide	281
Adapalene/Benzoyl Peroxide	121
Adapalene/Benzoyl Peroxide	311
Adapalene/Benzoyl Peroxide	109
Adapalene/Benzoyl Peroxide	6
Adapalene/Benzoyl Peroxide	337
Adapalene/Benzoyl Peroxide	52
Adapalene/Benzoyl Peroxide	320
Adapalene/Benzoyl Peroxide	37
Adapalene/Benzoyl Peroxide	4
Adapalene/Benzoyl Peroxide	58
Adapalene/Benzoyl Peroxide	278
Adapalene/Benzoyl Peroxide	48
Adapalene/Benzoyl Peroxide	3
Adapalene/Benzoyl Peroxide	291
Adapalene/Benzoyl Peroxide	36
Adapalene/Benzoyl Peroxide	0

Intervention	percent change (Mean)
	Inflammatory Lesion Counts	Noninflammatory Lesion Counts	Total Lesion Counts
Adapalene/Benzoyl Peroxide	-59.70	-58.80	-58.85

Intervention	Participants (Count of Participants)
	Hematology	Blood Chemistry	Urine Analysis
Adapalene/Benzoyl Peroxide	0	0	0

Intervention	Participants (Number)
	-1=Worse	0=Unchanged	1=Mild Improvement	2=Moderate Improvement	3=Clear
Benzoyl Peroxide 2.5% Cream	0	7	1	1	1
Benzoyl Peroxide 2.5% Cream Plus Moisturizing Lotion	0	6	1	2	1

Intervention	participants (Number)
	Clear	Almost Clear	Marked Improvement	Moderate Improvement	Minimal Improvement	No Change	Worse
Combination Therapy	3	40	27	16	5	8	1

Intervention	Percentage of participants (Number)
Benzoyl Peroxide/Clindamycin + Tazarotene	33
Benzoyl Peroxide/Clindamycin + Vehicle Cream	31
Benzoyl Peroxide Gel + Tazarotene	27
Clindamycin Gel + Tazarotene	39
Vehicle Gel + Tazarotene	22
Vehicle Gel + Vehicle Cream	13

Intervention	Percent change (Mean)
	ILC, n=101, 103, 105, 105, 104, 52	NILC, n=101, 103, 105, 105, 104, 52	TLC, n=101, 103, 105, 105, 104, 52
Benzoyl Peroxide Gel + Tazarotene	-62.4	-60.6	-62.0
Benzoyl Peroxide/Clindamycin + Tazarotene	-58.3	-58.0	-59.1
Benzoyl Peroxide/Clindamycin + Vehicle Cream	-62.4	-39.2	-47.9
Clindamycin Gel + Tazarotene	-65.7	-61.2	-63.4
Vehicle Gel + Tazarotene	-49.0	-53.1	-51.8
Vehicle Gel + Vehicle Cream	-33.5	-29.5	-31.5

Intervention	Percent change in lesion counts (Mean)
	Inflammatory Lesions	Non-inflammatory Lesions	Total Lesions
BPO Gel	-61.8	-50.8	-55.5
Clindamycin Gel	-58.1	-43.3	-49.2
Duac Low-dose (LD) Gel	-68.9	-53.9	-59.8
Vehicle Gel	-48.8	-34.0	-40.4

Intervention	scores on a scale (Mean)
	Itching, Week 2, n=297, 301, 305, 305	Itching, Week 4, n=298, 299, 299, 305	Itching, Week 8, n=297, 295, 293, 291	Itching, Week 12, n=297, 295, 294, 293	Burning/Stinging, Week 2, n=297, 301, 305, 305	Burning/Stinging, Week 4, n=298, 2991, 299, 305	Burning/Stinging, Week 8, n=297, 295, 293, 291	Burning/Stinging, Week 12, n=297, 295, 294, 293
BPO Gel	-0.04	-0.07	-0.08	-0.13	-0.02	-0.05	-0.05	-0.04
Clindamycin Gel	-0.18	-0.18	-0.24	-0.28	-0.06	-0.09	-0.09	-0.13
Duac Low-dose (LD) Gel	-0.11	-0.11	-0.16	-0.21	0.02	-0.06	-0.05	-0.09
Vehicle Gel	-0.06	-0.10	-0.08	-0.13	-0.05	-0.02	-0.06	-0.04

Intervention	scores on a scale (Mean)
	Erythema, Week 2, n=298, 302, 306, 306	Erythema, Week 4, n=298, 300, 299, 306	Erythema, Week 8, n=297, 296, 294, 293	Erythema, Week 12, n=297, 296, 296, 294	Dryness, Week 2, n=298, 302, 306, 306	Dryness, Week 4, n=298, 300, 299, 306	Dryness, Week 8, n=297, 296, 294, 293	Dryness, Week 12, n=297, 296, 296, 294	Peeling, Week 2, n=298, 302, 306, 306	Peeling, Week 4, n=298, 300, 299, 306	Peeling, Week 8, n=297, 296, 294, 293	Peeling, Week 12, n=297, 296, 296, 294
BPO Gel	-0.07	-0.08	-0.15	-0.17	0.09	0.08	0.05	-0.01	0.08	0.01	-0.01	-0.02
Clindamycin Gel	-0.01	-0.07	-0.08	-0.18	0.03	-0.02	-0.02	-0.10	0.02	0.00	-0.01	-0.06
Duac Low-dose (LD) Gel	-0.05	-0.07	-0.12	-0.17	0.07	0.05	0.00	-0.07	0.03	-0.01	-0.01	-0.08
Vehicle Gel	-0.02	-0.06	-0.08	-0.13	0.04	0.00	0.02	-0.04	0.02	0.00	0.00	-0.04

Intervention	Millimeters of mercury (mmHg) (Mean)
	Systolic blood pressure	Diastolic blood pressure
BPO Gel	0	0
Clindamycin Gel	0	1
Duac Low-dose (LD) Gel	0	0
Vehicle Gel	0	0

Intervention	days (Mean)
Duac Low-dose (LD) Gel	79.5
Clindamycin Gel	78.0
BPO Gel	78.0
Vehicle Gel	77.8

Intervention	lesion counts (Mean)
Duac Low-dose (LD) Gel	-43.0
Clindamycin Gel	-35.5
BPO Gel	-39.0
Vehicle Gel	-27.8

Intervention	Degrees centigrade (Mean)
Duac Low-dose (LD) Gel	-0.1
Clindamycin Gel	0.0
BPO Gel	0.0
Vehicle Gel	0.0

Intervention	lesion counts (Mean)
Duac Low-dose (LD) Gel	-18.2
Clindamycin Gel	-15.6
BPO Gel	-16.8
Vehicle Gel	-13.1

Intervention	participants (Number)
	Application Site Dermatitis	Application Site Hypersensitivity	Application Site Pruritus	Varicella
BPO Gel	0	1	1	0
Clindamycin Gel	0	0	0	0
Duac Low-dose (LD) Gel	1	0	0	0
Vehicle Gel	0	0	1	1

benzoyl peroxide

Description

Cross-References

Synonyms (668)

Research Excerpts

Overview

Effects

Actions

Treatment

Toxicity

Compound-Compound Interactions

Bioavailability

Dosage Studied

Occurs in Manufacturing (56 Product(s))

Product Categories

Products

Drug Classes (1)

Protein Targets (4)

Potency Measurements

Ceullar Components (1)

Bioassays (51)

Research

Studies (1,099)

Market Indicators

Research Demand Index: 72.42

Study Types

Clinical Trials (113)

Trial Overview

Trial Outcomes

Percent Change in Noniflammatory Lesion Counts

Percent Change in Total Lesion Counts

Success Rate on the Investigator's Global Assessment

Percent Change in Inflammatory Lesion Counts

Changes in Inflammatory Lesion Counts

Changes in Noninflammatory Lesion Counts

Number of Participant With Adverse Event (AE) and Serious Adverse Event (SAE)

Number of Participants With Local Tolerability Assessment For Dryness

Percent Change From Baseline in Inflammatory, Noninflammatory and Total Lesion Count at Month 12 LOCF

Number of Participants With Clinically Significant Abnormal Laboratory Parameters

Number of Participants With Local Tolerability Assessment For Erythema

Number of Participants With Local Tolerability Assessment For Scaling

Number of Participants With Local Tolerability Assessment For Stinging/Burning

Subject Reported Change From Baseline Scale

Adherence

Worst Post Baseline Tolerability Assessment - Scaling

Worst Post Baseline Tolerability Assessment - Erythema

Worst Post Baseline Tolerability Assessment - Dryness

Worst Post Baseline Tolerability Assessment - Burning/Stinging

Percent Change From Baseline in Total Lesion Counts

Global Severity Assessment Success

Global Assessment of Improvement From Baseline

Investigator Global Assessment (IGA) Maintenance Success at Week 24

Maintenance Success for Non-inflammatory Lesions at Week 24

Percent of Subjects With Adverse Events

Maintenance Success for Total Lesions at Week 24

Maintenance Success for Inflamatory Lesions at Week 24

Proportion of Participants With an ISGA Score of 0 or 1 at Week 12

Percent Change From Baseline to Week 12 in Each of 3 Lesion Counts (Total, Inflammatory, and Non-inflammatory)

Proportion of Participants With a Minimum 2-grade Improvement in the Investigator's Static Global Assessment (ISGA) Score From Baseline to Week 12

Absolute Change in Lesion Counts (Total, Inflammatory, and Non-inflammatory) From Baseline to Week 12

Mean Percent Change From Baseline to Week 12 in Lesion Counts (Total, Inflammatory, and Non-inflammatory)

Number of Participants Who Had an ISGA Score of 0 or 1 at Week 12

Mean Change From Baseline to Weeks 2, 4, 8, and 12 in Itching and Burning/Stinging

Mean Change From Baseline to Weeks 2, 4, 8, and 12 in Erythema, Dryness, and Peeling

Mean Change From Baseline to Week 12 in Systolic and Diastolic Blood Pressure

Number of Participants With Improvement of at Least 2 Grades in the Investigator's Static Global Assessment (ISGA) Score From Baseline to Week 12

Mean Duration of Study Product Use

Mean Change From Baseline to Week 12 in Total Lesion Counts

Mean Change From Baseline to Week 12 in Temperature

Mean Change From Baseline to Week 12 in Pulse Rate

Number of Participants Who Had a Subject Global Assessment (SGA) Score of 0 or 1 at Week 12

Mean Change From Baseline (BL) to Week 12 in Inflammatory Lesion Counts

Number of Participants Reporting the Indicated Treatment-emergent Adverse Events (AEs) Resulting in Study Product Discontinuation

Mean Change From Baseline to Week 12 in Non-inflammatory Lesion Counts

Number of Inflammatory Lesions (Papules and Pustules)

Percent Change in Total Acne Lesion Counts From Baseline to Week 16

Percent Change in Total Lesions (Chest and Back) From Baseline to Week 12

Change in Investigator Global Assessment (IGA)

Percentage of Particpants With IGA Score at Week 16

Percent (%) Change in Inflammatory Lesion Counts (Chest and Back) From Baseline to Week 12

Intervention	lesion counts (Mean)
Duac Low-dose (LD) Gel	-24.8
Clindamycin Gel	-19.8
BPO Gel	-22.2
Vehicle Gel	-14.8

Intervention	Lesions (Number)
	Subject 1 Day 0	Subject 1 Day 2	Subject 1 Day 7	Subject 1 Day 28	Subject 2 Day 0	Subject 2 Day 2	Subject 2 Day 7	Subject 2 Day 28	Subject 3 Day 0	Subject 3 Day 2	Subject 3 Day 7	Subject 3 Day 28	Subject 4 Day 0	Subject 4 Day 2	Subject 4 Day 7	Subject 4 Day 28	Subject 5 Day 0	Subject 5 Day 2	Subject 5 Day 7	Subject 5 Day 28	Subject 6 Day 0	Subject 6 Day 2	Subject 6 Day 7	Subject 6 Day 28	Subject 7 Day 0	Subject 7 Day 2	Subject 7 Day 7	Subject 7 Day 28	Subject 8 Day 0	Subject 8 Day 2	Subject 8 Day 7	Subject 8 Day 28	Subject 9 Day 0	Subject 9 Day 2	Subject 9 Day 7	Subject 9 Day 28	Subject 10 Day 0	Subject 10 Day 2	Subject 10 Day 7	Subject 10 Day 28
Papules: Benzoyl Peroxide 10.0% Cream Formulation #1	6	1	1	6	14	15	7	7	7	8	5	8	14	20	21	10	23	26	31	26	22	14	10	12	34	47	46	35	9	11	10	6	17	21	22	13	13	15	13	6
Papules: Benzoyl Peroxide 10.0% Cream Formulation #2	10	5	1	4	7	12	4	8	9	7	11	0	6	4	7	9	23	28	31	29	6	6	10	11	30	34	53	33	7	5	3	7	19	19	14	11	13	18	7	9
Pustules: Benzoyl Peroxide 10.0% Cream Formulation #1	3	0	0	1	2	1	0	0	0	0	3	0	4	1	0	1	1	18	0	1	2	0	1	1	6	3	3	6	1	0	0	0	1	0	0	0	2	0	1	1
Pustules: Benzoyl Peroxide 10.0% Cream Formulation #2	0	1	0	2	0	2	0	9	6	0	1	1	1	1	1	1	2	21	4	2	3	2	1	0	5	7	1	4	1	0	0	0	1	0	0	0	4	1	2	0

Intervention	Percent Change (Mean)
Benzoyl Peroxide Wash -Clindamycin Foam	-38.49
Benzoyl Peroxide Wash -Clindamycin Foam -Doxycycline Capsules	-46.11

Intervention	Percent change (Mean)
Benzoyl Peroxide Wash -Clindamycin Foam	-44.16
Benzoyl Peroxide Wash -Clindamycin Foam -Doxycycline Capsules	-41.74

Intervention	Units on a scale (Mean)
	Change from Baseline to Week 4	Change from Baseline to Week 8	Change from Baseline to Week 12	Change from Baseline to Week 16
Benzoyl Peroxide Wash -Clindamycin Foam	-0.42	-0.55	-1	-0.9
Benzoyl Peroxide Wash -Clindamycin Foam -Doxycycline Capsules	-0.61	-0.85	-1.09	-1.25

Intervention	Percent of participants (Number)
	% Clear skin	% Clear or Almost Clear	% Almost Clear	% Almost clear/ mild	% Mild	% Mild/ Moderate	% Moderate
Benzoyl Peroxide Wash -Clindamycin Foam	0	0	30	10	10	20	30
Benzoyl Peroxide Wash -Clindamycin Foam -Doxycycline Capsules	8.3	8.3	25	8.3	25	8.3	16.7

Intervention	Percent Change (Mean)
Benzoyl Peroxide Wash -Clindamycin Foam	-49.04
Benzoyl Peroxide Wash -Clindamycin Foam -Doxycycline Capsules	-45.44

Intervention	Percent Change (Mean)
Benzoyl Peroxide Wash -Clindamycin Foam	-25.27
Benzoyl Peroxide Wash -Clindamycin Foam -Doxycycline Capsules	-44.69

Intervention	Percent change (Mean)
Benzoyl Peroxide Wash -Clindamycin Foam	-52.70
Benzoyl Peroxide Wash -Clindamycin Foam -Doxycycline Capsules	-48.84

Intervention	Percent change (Mean)
Benzoyl Peroxide Wash -Clindamycin Foam	-38.43
Benzoyl Peroxide Wash -Clindamycin Foam -Doxycycline Capsules	-38.52